Author: "Aley, Parvinder K" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Aley, Parvinder K"' showing total 207 results

Start Over Author "Aley, Parvinder K"

207 results on '"Aley, Parvinder K"'

1. Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study

Author: de Oliveira Paiva, Hugo Diógenes, Smith, Catherin C, Brites, Carlos, Sprinz, Eduardo, Vasconcellos, Eduardo, Badal-Faesen, Sharlaa, Koen, Anthonet, Burgess, Lesley, Engelbrecht, Johannes, Vekemans, Johan, Kobielusz-Gembala, Iwona, Jones, Colin, Hirsch, Ian, Aksyuk, Anastasia, Wilkins, Deidre, Stanely, Ann Marie, Petropoulos, Christos J, Wrin, Terri, Rugieri, Sidelcina, Bennet, Jaclyn A, Greffrath, Johann, Sorio, Guilherme L, Mantyka, Jolanta, Costa Clemens, Sue Ann, Jepson, Brett, Bhorat, Qasim E, Ahmad, Abdullahi, Akhund, Tauseefullah, Aley, Parvinder K, Bansal, Himanshu, Bibi, Sagida, Kelly, Elizabeth J, Khan, Mark, Lambe, Teresa, Lombaard, Johan J, Matthews, Sam, Pipolo Milan, Eveline, Olsson, Urban, Ramasamy, Maheshi N, Moura de Oliveira Paiva, Maria Sanali, Seegobin, Seth, Shoemaker, Kathryn, Szylak, Ameena, Villafana, Tonya, Pollard, Andrew J, and Green, Justin A
Published: 2024
Full Text: View/download PDF

2. Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents

Author: Ratcliffe, Helen, Tiley, Karen S., Longet, Stephanie, Tonry, Claire, Roarty, Cathal, Watson, Chris, Amirthalingam, Gayatri, Vichos, Iason, Morey, Ella, Douglas, Naomi L., Marinou, Spyridoula, Plested, Emma, Aley, Parvinder K., Galiza, Eva, Faust, Saul N., Hughes, Stephen, Murray, Clare, Roderick, Marion R., Shackley, Fiona, Oddie, Sam, Lee, Tim W.R., Turner, David P.J., Raman, Mala, Owens, Stephen, Turner, Paul J., Cockerill, Helen, Lopez Bernal, Jamie, Ijaz, Samreen, Poh, John, Shute, Justin, Linley, Ezra, Borrow, Ray, Hoschler, Katja, Brown, Kevin E., Carroll, Miles W., Klenerman, Paul, Dunachie, Susanna J., Ramsay, Mary, Voysey, Merryn, Waterfield, Thomas, and Snape, Matthew D.
Published: 2023
Full Text: View/download PDF

3. Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland

Author: Wildman, Eden, Rampling, Tommy, Morris, Sheila, Shoemaker, Kathryn, Aksyuk, Anastasia, Padilla, Marcelino Giune, Roe, Tiffany, Petropoulos, Christos J, Wrin, Terri, Colton, Hayley, Bisnauthsing, Karen, Smith, Catherine, Leeman, Lucy, Galloway, James, Nagra, Deepak, Lazarus, Rajeka, Penciu, Florentina, Hunter, Ewan, Sahdev, Anju, Turner, David, Royal, Simon, Uriel, Alison, Ustianowski, Andrew, Moran, Ed, Green, Christopher, Desai, Amisha, Lakeman, Nicki, Moore, Patrick, Whittington, Ashley, Kobielusz Gembala, Iwona, Konieczny, Marek, Ramasamy, Maheshi N, Kelly, Elizabeth J, Seegobin, Seth, Dargan, Paul I, Payne, Ruth, Libri, Vincenzo, Adam, Matthew, Aley, Parvinder K, Martinez-Alier, Nuria, Church, Alison, Jepson, Brett, Khan, Mark, Matthews, Sam, Townsend, G Todd, Vekemans, Johan, Bibi, Sagida, Swanson, Phillip A, II, Lambe, Teresa, Pangalos, Menelas N, Villafana, Tonya, Pollard, Andrew J, and Green, Justin A
Published: 2023
Full Text: View/download PDF

4. Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial

Author: Kelly, Eimear, Greenland, Melanie, de Whalley, Philip C.S., Aley, Parvinder K., Plested, Emma L., Singh, Nisha, Koleva, Stanislava, Tonner, Sharon, Macaulay, Grace C., Read, Robert C., Ramsay, Mary, Cameron, J.Claire, Turner, David P.J., Heath, Paul T., Bernatoniene, Jolanta, Connor, Philip, Cathie, Katrina, Faust, Saul N., Banerjee, Indraneel, Cantrell, Liberty, Mujadidi, Yama F., Belhadef, Hanane Trari, Clutterbuck, Elizabeth A., Anslow, Rachel, Valliji, Zara, James, Tim, Hallis, Bassam, Otter, Ashley David, Lambe, Teresa, Nguyen-Van-Tam, Jonathan S., Minassian, Angela M., Liu, Xinxue, and Snape, Matthew D.
Published: 2023
Full Text: View/download PDF

5. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial

Author: Liu, Xinxue, Munro, Alasdair P S, Wright, Annie, Feng, Shuo, Janani, Leila, Aley, Parvinder K, Babbage, Gavin, Baker, Jonathan, Baxter, David, Bawa, Tanveer, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna, Dodd, Kate, Enever, Yvanne, Fox, Lauren, Qureshi, Ehsaan, Goodman, Anna L., Green, Christopher A, Haughney, John, Hicks, Alexander, Jones, Christine E, Kanji, Nasir, van der Klaauw, Agatha A., Libri, Vincenzo, Llewelyn, Martin J, Mansfield, Rebecca, Maallah, Mina, McGregor, Alastair C, Minassian, Angela M., Moore, Patrick, Mughal, Mehmood, Mujadidi, Yama F, Belhadef, Hanane Trari, Holliday, Kyra, Osanlou, Orod, Osanlou, Rostam, Owens, Daniel R, Pacurar, Mihaela, Palfreeman, Adrian, Pan, Daniel, Rampling, Tommy, Regan, Karen, Saich, Stephen, Saralaya, Dinesh, Sharma, Sunil, Sheridan, Ray, Stokes, Matthew, Thomson, Emma C, Todd, Shirley, Twelves, Chris, Read, Robert C., Charlton, Sue, Hallis, Bassam, Ramsay, Mary, Andrews, Nick, Lambe, Teresa, Nguyen-Van-Tam, Jonathan S, Cornelius, Victoria, Snape, Matthew D, and Faust, Saul N
Published: 2023
Full Text: View/download PDF

6. Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial

Author: Madhi, Shabir A, Kwatra, Gaurav, Richardson, Simone I, Koen, Anthonet L, Baillie, Vicky, Cutland, Clare L, Fairlie, Lee, Padayachee, Sherman D, Dheda, Keertan, Barnabas, Shaun L, Bhorat, Qasim Ebrahim, Briner, Carmen, Ahmed, Khatija, Aley, Parvinder K, Bhikha, Sutika, Bhorat, A E, Esmail, Aliasgar, Horne, Elizea, Kaldine, Haajira, Mukendi, Christian K, Madzorera, Vimbai Sharon, Manamela, Nelia P, Masilela, Mduduzi, Hermanus, S Tandile, Motlou, Thopisang, Mzindle, Nonkululeko, Oelofse, Suzette, Patel, Faeezah, Rhead, Sarah, Rossouw, Lindie, Taoushanis, Carol, van Eck, Samuel, Lambe, Teresa, Gilbert, Sarah C, Pollard, Andrew J, Moore, Penny L, and Izu, Alane
Published: 2023
Full Text: View/download PDF

7. Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial

Author: Munro, Alasdair P.S., Bartholomew, Jazz, Presland, Laura, Horswill, Sarah, Warren, Sarah, Varkonyi-Clifford, Sophie, Saich, Stephen, Adams, Kirsty, Ricamara, Marivic, Turner, Nicola, Yee Ting, Nicole Y., Whittley, Sarah, Rampling, Tommy, Desai, Amisha, Brown, Claire H., Qureshi, Ehsaan, Gokani, Karishma, Naker, Kush, Kellett Wright, Johanna K., Williams, Rachel L., Riaz, Tawassal, Penciu, Florentina D., Carson, Amy, Di Maso, Claudio, Mead, Gracie, Howe, Elizabeth G., Vichos, Iason, Ghulam Farooq, Mujtaba, Noristani, Rabiullah, Yao, Xin L., Oldfield, Neil J., Hammersley, Daniel, Belton, Sue, Royal, Simon, San Francisco Ramos, Alberto, Hultin, Cecilia, Galiza, Eva P., Crook, Rebecca, Bula, Marcin, Fyles, Fred, Burhan, Hassan, Maelin, Flora, Hughes, Elen, Okenyi, Emmanuel, Shaw, Robert H, Liu, Xinxue, Stuart, Arabella S V, Greenland, Melanie, Aley, Parvinder K, Andrews, Nick J, Cameron, J Claire, Charlton, Sue, Clutterbuck, Elizabeth A, Collins, Andrea M, Dejnirattisai, Wanwisa, Dinesh, Tanya, Faust, Saul N, Ferreira, Daniela M, Finn, Adam, Green, Christopher A, Hallis, Bassam, Heath, Paul T, Hill, Helen, Lambe, Teresa, Lazarus, Rajeka, Libri, Vincenzo, Long, Fei, Mujadidi, Yama F, Plested, Emma L, Morey, Ella R, Provstgaard-Morys, Samuel, Ramasamy, Maheshi N, Ramsay, Mary, Read, Robert C, Robinson, Hannah, Screaton, Gavin R, Singh, Nisha, Turner, David P J, Turner, Paul J, Walker, Laura L, White, Rachel, Nguyen-Van-Tam, Jonathan S, and Snape, Matthew D
Published: 2022
Full Text: View/download PDF

8. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

Author: Munro, Alasdair P S, Feng, Shuo, Janani, Leila, Cornelius, Victoria, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna, Dodd, Kate, Enever, Yvanne, Qureshi, Ehsaan, Goodman, Anna L, Green, Christopher A, Harndahl, Linda, Haughney, John, Hicks, Alexander, van der Klaauw, Agatha A, Kanji, Nasir, Libri, Vincenzo, Llewelyn, Martin J, McGregor, Alastair C, Minassian, Angela M, Moore, Patrick, Mughal, Mehmood, Mujadidi, Yama F, Holliday, Kyra, Osanlou, Orod, Osanlou, Rostam, Owens, Daniel R, Pacurar, Mihaela, Palfreeman, Adrian, Pan, Daniel, Rampling, Tommy, Regan, Karen, Saich, Stephen, Bawa, Tanveer, Saralaya, Dinesh, Sharma, Sunil, Sheridan, Ray, Maallah, Mina, Thomson, Emma C, Todd, Shirley, Twelves, Chris, Read, Robert C, Charlton, Sue, Hallis, Bassam, Ramsay, Mary, Andrews, Nick, Lambe, Teresa, Nguyen-Van-Tam, Jonathan S, Snape, Matthew D, Liu, Xinxue, Faust, Saul N, Riordan, Andrew, Ustianowski, Andrew, Rogers, Chris, Katechia, Kashyap, Cooper, Alison, Freedman, Andrew, Hughes, Rachel, Grundy, Lynne, Tudor Jones, Lona, Harrison, Elizabeth, Snashall, Emma, Mallon, Lewis, Burton, Katharine, Storton, Kim, Munusamy, Malathi, Tandy, Bridget, Egbo, Akamino, Cox, Stephen, Ahmed, Nabeela Nazir, Shenoy, Anil, Bousfield, Rachel, Wixted, Donna, Gutteridge, Helen, Mansfield, Becky, Herbert, Christopher, Murira, Jennifer, Calderwood, James, Barker, Dominique, Brandon, Jacqueline, Tulloch, Hayley, Colquhoun, Suzie, Thorp, Helen, Radford, Helen, Evans, Julie, Baker, Helena, Thorpe, Jeanette, Batham, Sally, Hailstone, Jessica, Phillips, Rachael, Kumar, Dileep, Westwell, Fran, Sturdy, Ann, Barcella, Lara, Soussi, Najwa, Mpelembue, Mushiya, Raj, Sreena, Sharma, Rajni, Corrah, Tumena, John, Laurence, Whittington, Ashley, Roche, Siobhan, Wagstaff, Lynda, Farrier, Adam, Bisnauthsing, Karen, Abeywickrama, Movin, Spence, Niamh, Packham, Alice, Serafimova, Teona, Aslam, Suahil, McGreevy, Caitlin, Borca, Alessandro, DeLosSantosDominguez, Pamela, Palmer, Emily, Broadhead, Samantha, Farooqi, Sadaf, Piper, Jo, Weighell, Rowena, Pickup, Lorinda, Shamtally, Djamila, Domingo, Jason, Kourampa, Evgenia, Hale, Colin, Gibney, Jennifer, Stackpoole, Michael, Rashid-Gardner, Zalina, Lyon, Rebecca, McDonnell, Chloe, Cole, Christine, Stewart, Anna, McMillan, Gillian, Savage, Mary, Beckett, Helen, Moorbey, Chantelle, Desai, Amisha, Brown, Claire, Naker, Kush, Gokani, Karishma, Trinham, Charlotte, Sabine, Charlette, Moore, Sophie, Hurdover, Steve, Justice, Edwin, Stone, Megan, Plested, Emma, Ferreira Da Silva, Carla, White, Rachel, Robinson, Hannah, Turnbull, Iain, Morshead, Gertraud, Drake-Brockman, Rachael, Smith, Catherine, Li, Grace, Kasanyinga, Mwila, Clutterbuck, Elizabeth A, Bibi, Sagida, Singh, Michael, Champaneri, Trishna, Irwin, Margaret, Khan, Mohammed, Kownacka, Alicia, Nabunjo, Martha, Osuji, Carol, Hladkiwskyj, John, Galvin, Dominic, Patel, Gita, Grierson, Jacques, Males, Samantha, Askoolam, Krishna, Barry, Joshua, Mouland, Johanna, Longhurst, Beverley, Moon, Maria, Giddins, Beth, Pereira Dias Alves, Carlota, Richmond, Leah, Minnis, Christine, Baryschpolec, Sonia, Elliott, Scott, Fox, Lauren, Graham, Victoria, Baker, Natalie, Godwin, Kerry, Buttigieg, Karen, Knight, Chanice, Brown, Phillip, Lall, Paminder, Shaik, Imam, Chiplin, Emily, Brunt, Emily, Leung, Stephanie, Allen, Lauren, Thomas, Steve, Fraser, Sara, Choi, Bea, Gouriet, Jade, Perkins, Jonathan, Gowland, Andrew, Macdonald, Jonathan, Seenan, John Paul, Starinskij, Igor, Seaton, Andrew, Peters, Erica, Singh, Stephen, Gardside, Ben, Bonnaud, Avril, Davies, Ceri, Gordon, Elizabeth, Keenan, Samantha, Hall, Jane, Wilkins, Suzanne, Tasker, Suzanne, James, Rob, Seath, Ingrid, Littlewood, Kelly, Newman, Joseph, Boubriak, Iryna, Suggitt, Debbie, Haydock, Helen, Bennett, Sara, Woodyatt, Wiesia, Hughes, Kerry, Bell, Judith, Coughlan, Tricia, van Welsenes, Donald, Kamal, Mohammed, Cooper, Chris, Tunstall, Simon, Ronan, Nicholas, Cutts, Rebecca, Dare, Tracey, Yim, Yee Ting Nicole, Whittley, Sarah, Hamal, Shama, Ricamara, Marivic, Adams, Kirsty, Baker, Holly, Driver, Kimberley, Turner, Nicola, Rawlins, Todd, Roy, Subarna, Merida-Morillas, Marta, Sakagami, Yukari, Andrews, Antonette, Goncalvescordeiro, Lillian, Stokes, Matthew, Ambihapathy, Wythehi, Spencer, Joanne, Parungao, Nina, Berry, Lisa, Cullinane, James, Presland, Laura, Ross Russell, Amy, Warren, Sarah, Baker, Jonathan, Oliver, Abigail, Buadi, Amanda, Lee, Kim, Haskell, Louise, Romani, Rossana, Bentley, Ian, Whitbred, Tim, Fowler, Simon, Gavin, John, Magee, Alan, Watson, Tara, Nightingale, Kari, Marius, Phedra, Summerton, Eloise, Locke, Emily, Honey, Thomas, Lingwood, Aidan, de la Haye, Anastasia, Elliott, Ryan Stephen, Underwood, Karen, King, Mikayala, Davies-Dear, Sharon, Horsfall, Emily, Chalwin, Olivia, Burton, Holly, Edwards, Christopher J, Welham, Benjamin, Appleby, Kim, Dineen, Emily, Garrahy, Sarah, Hall, Fran, Ladikou, Eleni, Mullan, Dee, Hansen, Daniel, Campbell, Marion, Dos Santos, Filipa, Lakeman, Nicki, Branney, Debbie, Vamplew, Luke, Hogan, Alison, Frankham, Jorden, Wiselka, Martin, Vail, Denny, Wenn, Victoria, Renals, Valerie, Ellis, Kate, Lewis-Taylor, Jessica, Habash-Bailey, Haniah, Magan, Javier, and Hardy, Anna
Published: 2022
Full Text: View/download PDF

9. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial

Author: Aboagye, J, Ambihapathy, W, Baker, JF, Beales, ER, Boon, A, Brampton, R, Branch, NM, Cooper, R, Cornish, EL, Cuevas-Asturias, S, Danos, Z, Davies, S, de Luna George, L, Drury, R, Flaxman, A, Fowler, J, Galiza, E, Godfrey, L, Haskell, L, Hillson, K, Hultin, CL, Koleva, S, Lees, E, Mabbett, R, Muller, J, Munro, APS, Oliver, AL, Owens, DR, Pearce, JP, Rajan, M, Ratcliffe, H, Rowbotham, I, Salter, S, Sanders, H, Sapuan, SS, Sharpe, H, Sheehan, E, Sutton, N, Thaygaraja, G, Thomson-Hill, S, Ulaszewska, M, Woods, D, Bristol Clinical Research Nurse Team, Li, Grace, Cappuccini, Federica, Marchevsky, Natalie G, Aley, Parvinder K, Aley, Robert, Anslow, Rachel, Bibi, Sagida, Cathie, Katrina, Clutterbuck, Elizabeth, Faust, Saul N, Feng, Shuo, Heath, Paul T, Kerridge, Simon, Lelliott, Alice, Mujadidi, Yama, Ng, Khuen Foong, Rhead, Sarah, Roberts, Hannah, Robinson, Hannah, Roderick, Marion R, Singh, Nisha, Smith, David, Snape, Matthew D, Song, Rinn, Tang, Karly, Yao, Andy, Liu, Xinxue, Lambe, Teresa, and Pollard, Andrew J
Published: 2022
Full Text: View/download PDF

10. Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.

Author: Liu, Xinxue, Munro, Alasdair P S, Feng, Shuo, Janani, Leila, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna, Dejnirattisai, Wanwisa, Dodd, Kate, Enever, Yvanne, Qureshi, Ehsaan, Goodman, Anna L., Green, Christopher A, Harndahl, Linda, Haughney, John, Hicks, Alexander, van der Klaauw, Agatha A., Kwok, Jonathan, Libri, Vincenzo, Llewelyn, Martin J, McGregor, Alastair C, Minassian, Angela M., Moore, Patrick, Mughal, Mehmood, Mujadidi, Yama F, Holliday, Kyra, Osanlou, Orod, Osanlou, Rostam, Owens, Daniel R, Pacurar, Mihaela, Palfreeman, Adrian, Pan, Daniel, Rampling, Tommy, Regan, Karen, Saich, Stephen, Serafimova, Teona, Saralaya, Dinesh, Screaton, Gavin R, Sharma, Sunil, Sheridan, Ray, Sturdy, Ann, Supasa, Piyada, Thomson, Emma C, Todd, Shirley, Twelves, Chris, Read, Robert C., Charlton, Sue, Hallis, Bassam, Ramsay, Mary, Andrews, Nick, Lambe, Teresa, Nguyen-Van-Tam, Jonathan S, Cornelius, Victoria, Snape, Matthew D, and Faust, Saul N
Published: 2022
Full Text: View/download PDF

11. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

Author: Stuart, Arabella S V, Shaw, Robert H, Liu, Xinxue, Greenland, Melanie, Aley, Parvinder K, Andrews, Nick J, Cameron, J C, Charlton, Sue, Clutterbuck, Elizabeth A, Collins, Andrea M, Darton, Tom, Dinesh, Tanya, Duncan, Christopher J A, England, Anna, Faust, Saul N, Ferreira, Daniela M, Finn, Adam, Goodman, Anna L, Green, Christopher A, Hallis, Bassam, Heath, Paul T, Hill, Helen, Horsington, Bryn M, Lambe, Teresa, Lazarus, Rajeka, Libri, Vincenzo, Lillie, Patrick J, Mujadidi, Yama F, Payne, Ruth, Plested, Emma L, Provstgaard-Morys, Samuel, Ramasamy, Maheshi N, Ramsay, Mary, Read, Robert C, Robinson, Hannah, Screaton, Gavin R, Singh, Nisha, Turner, David P J, Turner, Paul J, Vichos, Iason, White, Rachel, Nguyen-Van-Tam, Jonathan S, and Snape, Matthew D
Published: 2022
Full Text: View/download PDF

12. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Author: Feng, Shuo, Phillips, Daniel J., White, Thomas, Sayal, Homesh, Aley, Parvinder K., Bibi, Sagida, and Dold, Christina
Subjects: Immune response -- Analysis, Viral antibodies -- Measurement, Antibodies -- Measurement, Biological sciences, Health
Abstract: The global supply of COVID-19 vaccines remains limited. An understanding of the immune response that is predictive of protection could facilitate rapid licensure of new vaccines. Data from a randomized efficacy trial of the ChAdOx1 nCoV-19 (AZD1222) vaccine in the United Kingdom was analyzed to determine the antibody levels associated with protection against SARS-CoV-2. Binding and neutralizing antibodies at 28 days after the second dose were measured in infected and noninfected vaccine recipients. Higher levels of all immune markers were correlated with a reduced risk of symptomatic infection. A vaccine efficacy of 80% against symptomatic infection with majority Alpha (B.1.1.7) variant of SARS-CoV-2 was achieved with 264 (95% CI: 108, 806) binding antibody units (BAU)/ml: and 506 (95% CI: 135, not computed (beyond data range) (NC)) BAU/ml for anti-spike and anti-RBD antibodies, and 26 (95% CI: NC, NC) international unit (IU)/ml and 247 (95% CI: 101, NC) normalized neutralization titers (NF.sub.50) for pseudovirus and live-virus neutralization, respectively. Immune markers were not correlated with asymptomatic infections at the 5% significance level. These data can be used to bridge to new populations using validated assays, and allow extrapolation of efficacy estimates to new COVID-19 vaccines. Defined levels of SARS-CoV-2-specific binding and neutralizing antibodies elicited by the COVID-19 vaccine ChAdOx1 nCoV-19 are identified as correlates of protection against symptomatic infection., Author(s): Shuo Feng [sup.1] , Daniel J. Phillips [sup.1] , Thomas White [sup.2] , Homesh Sayal [sup.2] , Parvinder K. Aley [sup.1] , Sagida Bibi [sup.1] , Christina Dold [sup.1] [...]
Published: 2021
Full Text: View/download PDF

13. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Author: Riordan, Andrew, Ustianowski, Andrew, Rogers, Chris A, Hughes, Stephen, Longshaw, Laura, Stockport, Jane, Hughes, Rachel, Grundy, Lynne, Tudor Jones, Lona, Guha, Arpan, Snashall, Emma, Eadsforth, Tom, Reeder, Sally, Storton, Kim, Munusamy, Malathi, Tandy, Bridget, Egbo, Akamino, Cox, Stephen, Ahmed, Nabeela Nazir, Shenoy, Anil, Bousfield, Rachel, Wixted, Donna, Gutteridge, Helen, Mansfield, Becky, Herbert, Christopher, Holliday, Kyra, Calderwood, James, Barker, Dominique, Brandon, Jacqueline, Tulloch, Hayley, Colquhoun, Suzie, Thorp, Helen, Radford, Helen, Evans, Julie, Baker, Helena, Thorpe, Jeanette, Batham, Sally, Hailstone, Jessica, Phillips, Rachael, Kumar, Dileep, Westwell, Fran, Makia, Fiona, Hopkins, NinaSimone, Barcella, Lara, Mpelembue, Mushiya, dabagh, Maja, lang, Matilda, khan, Farida, Adebambo, Olumide, Chita, Sunder, Corrah, Tumena, Whittington, Ashley, John, Laurence, Roche, Siobhan, Wagstaff, Lynda, Farrier, Adam, Bisnauthsing, Karen, Serafimova, Teona, Nanino, Elisa, Cooney, Enya, Wilson-Goldsmith, Jaimie, Nguyen, Hanna, Mazzella, Andrea, Jackson, Beth, Aslam, Suahil, Bawa, Tanveer, Broadhead, Samantha, Farooqi, Sadaf, Piper, Jo, Weighell, Rowena, Pickup, Lorinda, Shamtally, Djamila, Domingo, Jason, Kourampa, Evgenia, Hale, Colin, Gibney, Jennifer, Stackpoole, Michael, Rashid-Gardner, Zalina, Lyon, Rebecca, McDonnell, Chloe, Cole, Christine, Stewart, Anna, McMillan, Gillian, Savage, Mary, Beckett, Helen, Moorbey, Chantelle, Desai, Amisha, Brown, Claire, Naker, Kush, Qureshi, Ehsaan, Trinham, Charlotte, Sabine, Charlotte, Moore, Sophie, Hurdover, Steve, Justice, Edwin, Smith, David, Plested, Emma, Ferreira Da Silva, Carla, White, Rachel, Robinson, Hannah, Cifuentes, Liliana, Morshead, Gertraud, Drake-Brockman, Rachael, Kinch, Patrick, Kasanyinga, Mwila, Clutterbuck, Elizabeth A., Bibi, Sagida, Stuart, Arabella SV, Shaw, Robert H, Singh, Michael, Champaneri, Trishna, Irwin, Margaret, Khan, Mohammed, Kownacka, Alicja, Nabunjo, Martha, Osuji, Carool, Hladkiwskyj, John, Galvin, Dominic, Patel, Gita, Mouland, Johanna, Longhurst, Beverley, Moon, Maria, Giddins, Beth, Pereira Dias Alves, Carlota, Richmond, Leah, Minnis, Christine, Baryschpolec, Sonia, Elliott, Scott, Fox, Lauren, Graham, Victoria, Baker, Natalie, Godwin, Kerry, Buttigieg, Karren, Knight, Chanice, Brown, Phillip, Lall, Paminder, Shaik, Imam, Chiplin, Emily, Brunt, Emily, Leung, Stephanie, Allen, Lauren, Thomas, Steve, Fraser, Sara, Choi, Bea, Gouriet, Jade, Freedman, Andrew, Perkins, Jonathan, Gowland, Andrew, Macdonald, Jonathan, Seenan, John Paul, Starinskij, Igor, Seaton, Andrew, Peters, Erica, Singh, Stephen, Gardside, Ben, Bonnaud, Avril, Davies, Ceri, Gordon, Elizabeth, Keenan, Samantha, Hall, Jane, Wilkins, Suzanne, Tasker, Suzanne, James, Rob, Seath, Ingrid, Littlewood, Kelly, Newman, Joseph, Boubriak, Iryna, Suggitt, Debbie, Haydock, Helen, Bennett, Sara, Woodyatt, Wiesia, Hughes, Kerry, Bell, Judith, Coughlan, Tricia, van Welsenes, Donald, Kamal, Mohammed, Cooper, Chris, Tunstall, Simon, Ronan, Nicholas, Cutts, Rebecca, Dare, Tracey, Yim, Yee Ting Nicole, Whittley, Sarah, Ricamara, Marivic, Hamal, Shama, Adams, Kirsty, Baker, Holly, Driver, Kimberley, Turner, Nicola, Rawlins, Todd, Roy, Subarna, Merida-Morillas, Marta, Sakagami, Yukari, Andrews, Antonette, Goncalves cordeiro, Lillian, Stokes, Matthew, Ambihapathy, Wythehi, Spencer, Joanne, Parungao, Nina, Berry, Lisa, Cullinane, James, Presland, Laura, Ross-Russell, Amy, Warren, Sarah, Baker, Jonathan, Oliver, Abigail, Buadi, Amanda, Lee, Kim, Haskell, Louise, Romani, Rossana, Bentley, Ian, Whitbred, Tim, Fowler, Simon, Gavin, John, Magee, Alan, Watson, Tara, Nightingale, Kari, Marius, Phedra, Summerton, Eloise, Locke, Emily, Honey, Thomas, Lingwood, Aidan, de la Haye, Anastasia, Elliott, Ryan Stephen, Underwood, Karen, King, Mikayala, Davies-Dear, Sharon, Horsfall, Emily, Chalwin, Olivia, Burton, Holly, Edwards, Christopher J, Welham, Benjamin, Garrahy, Sarah, Hall, Fran, Ladikou, Eleni, Mullan, Dee, Hansen, Daniel, Campbell, Marion, Dos Santos, Filipa, Habash-Bailey, Haniah, Lakeman, Nicki, Branney, Debbie, Vamplew, Luke, Hogan, Alison, Frankham, Jorden, Wiselka, Martin, Vail, Dennyl, Wenn, Victoria, Renals, Valerie, Ellis, Kate, Lewis-Taylor, Jessica, Magan, Javier, Hardy, Anna, Appleby, Kim, Munro, Alasdair P S, Janani, Leila, Cornelius, Victoria, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna, Dodd, Kate, Enever, Yvanne, Gokani, Karishma, Goodman, Anna L, Green, Christopher A, Harndahl, Linda, Haughney, John, Hicks, Alexander, van der Klaauw, Agatha A, Kwok, Jonathan, Lambe, Teresa, Libri, Vincenzo, Llewelyn, Martin J, McGregor, Alastair C, Minassian, Angela M, Moore, Patrick, Mughal, Mehmood, Mujadidi, Yama F, Murira, Jennifer, Osanlou, Orod, Osanlou, Rostam, Owens, Daniel R, Pacurar, Mihaela, Palfreeman, Adrian, Pan, Daniel, Rampling, Tommy, Regan, Karen, Saich, Stephen, Salkeld, Jo, Saralaya, Dinesh, Sharma, Sunil, Sheridan, Ray, Sturdy, Ann, Thomson, Emma C, Todd, Shirley, Twelves, Chris, Read, Robert C, Charlton, Sue, Hallis, Bassam, Ramsay, Mary, Andrews, Nick, Nguyen-Van-Tam, Jonathan S, Snape, Matthew D, Liu, Xinxue, and Faust, Saul N
Published: 2021
Full Text: View/download PDF

14. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial

Author: Adams, Kirsty, Alaee, Seema, Aley, Parvinder K., Allum, Emma, Anthony, Sally, Ashton, Kate, Awal, Tanya, Barnett, Liz, Barratt, Alison, Barron, Charlotte, Baum, Holly, Beard, Chloe, Bennett, Lorna, Bird, Samuel, Bishop, Sarah, Bisset, Jess, Bodalia, Pritesh, Bowles, Jane, Bowyer, Catherine, Bradburn, Kirstie, Bray, Jonathan J.H., Bressington, Catherine, Brimfield, Matthew, Broad, Lauren, Brown, Pauline, Brydon-Hill, Ruth, Burge, Sharon, Carmichael, David, Chohan, Gurjit, Clark, Tonia, Close, Adrianne, Coleman, Tom, Cowley, Claire, Cranfield, Charlotte, Cross, Eleanor, D'Agostino, Alyssa, D'Arcangelo, Silvia, David Otter, Ashley, Davies, Kate, Davies, Catrin, Davies, Ru, Davies, Louisa, Driver, Kimberley, Eglinton, Charlotte, Ekblad, Charlotte, Eldridge, Emma, Evans, Teriann, Evans, Mim, Evans, Isabel, F Mujadidi, Yama, Farrow, Amanda, Faulkner, Beverley, Feltham, Sally, Figueirido, Susan, Ford, Jamie, Foxwell, David, Frayling, Sharon, Gardiner, Sophie, Gooch, Karen E., Goodwin, Jayne, Halliday, Alice, Hamal, Shama, Harrhy, Sarah, Harris, Andrew, Haxton, Lesley, Haynes, Matthew, Hazell, Mae, Hembrough, Tracey, Hewson, Jacqueline, Hicks, Bethany, Higgins, Thomas, Hill, Michelle, Hills, Alex, Hilton, Zoe, Hitchings, Benjamin, Hua, Cheryl, Iftikhar, Hina, Iqbal, Attya, Jones, Laura, Jones, Nicola, Kellett Wright, Johanna, Kidd, Sarah, Kirby, Alison, Knibbs, Lucy, Lamb, Jenny, Langton, Helen, Leach, Rwth, Lewis-Clarke, Phoebe, Lloyd, Amy, Maclean, Kirsty, Manning, Nicola, Marriott, Anthony, McFadzean, Isobel Joy, McLaughlin, Maeve, McQueen, Alison, Mills, Bianca, Naik, Gurudutt, Nicholls, Lisa, Norman, Chris, Northcott, Keren, Nyland, Kerry, Oliver, Catherine, Oliver, Elizabeth, Oliver, Jennifer, Owen, Diana, Paterson, Jemma, Pearce, Lauren, Pegler, Suzannah, Price, Zoe, Pynsent, William B., Ramos, Lidia, Rampling, Tommy, Rea, David, Regan, Karen, Riaz, Tawassal, Ricamara, Marivic, Rice, Danielle, Rich, Melody, Roots, Marianne, Ryan, Kathryn Ann, Sakagami, Yukari, Salem, Ahmed, Salter-Hewitt, Jade, Samuels, Michelle, Santoloce, Silvia, Seaman, Siwan, Seneviratne, Michael, Shankland, Sara, Silva, Louise, Smart, Katie, Smith, Rachel M., Smith, Joyce, Stringer, Rebecca, Talbot, Helen, Tarling, Teresa, Taylor, Sarah Louise, Thomas, Amy, Tilzey, Grace, Townley, Gina, Trembath, Lisa, Turkentine, Kate, Turner, Kelly, Tyler, Jenny, Ugoji, Jacinta, Wale, Katharine, Walker-Smith, Terrie, Walton, Maggie, Warnes, Barbara, Whittley, Sarah, Williams, Jennie, Williams, Gail, Williamson, Kevin, Yim, Yee Ting Nicole, Youlden, Nicola, Lazarus, Rajeka, Baos, Sarah, Cappel-Porter, Heike, Carson-Stevens, Andrew, Clout, Madeleine, Culliford, Lucy, Emmett, Stevan R, Garstang, Jonathan, Gbadamoshi, Lukuman, Hallis, Bassam, Harris, Rosie A, Hutton, David, Jacobsen, Nick, Joyce, Katherine, Kaminski, Rachel, Libri, Vincenzo, Middleditch, Alex, McCullagh, Liz, Moran, Ed, Phillipson, Adrian, Price, Elizabeth, Ryan, John, Thirard, Russell, Todd, Rachel, Snape, Matthew D, Tucker, David, Williams, Rachel Lauren, Nguyen-Van-Tam, Jonathan S, Finn, Adam, and Rogers, Chris A
Published: 2021
Full Text: View/download PDF

15. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Author: Adlou, Syed, Aley, Robert, Ali, Aabidah, Anslow, Rachel, Baker, Megan, Baker, Phillip, Barrett, Jordan R., Bates, Louise, Beadon, Kirsten, Beckley, Rebecca, Bell, Jonathan, Bellamy, Duncan, Beveridge, Amy, Bissett, Cameron, Blackwell, Luke, Bletchly, Heather, Boyd, Amy, Bridges-Webb, Alice, Brown, Charlie, Byard, Nicholas, Camara, Susana, Cifuentes Gutierrez, Liliana, Collins, Andrea M., Cooper, Rachel, Crocker, Wendy E.M., Darton, Thomas C., Davies, Hannah, Davies, Judith, Demissie, Tesfaye, Di Maso, Claudio, Dinesh, Tanya, Donnellan, Francesca R., Douglas, Alexander D., Drake-Brockman, Rachael, Duncan, Christopher J.A., Elias, Sean C., Emary, Katherine R.W., Ghulam Farooq, Mutjaba, Faust, Saul N., Felle, Sally, Ferreira, Daniela, Ferreira Da Silva, Carla, Finn, Adam, Ford, Karen J., Francis, Emma, Furze, Julie, Fuskova, Michelle, Galiza, Eva, Gibertoni Cruz, Ana, Godfrey, Leila, Goodman, Anna L., Green, Catherine, Green, Christopher A., Greenwood, Nicola, Harrison, Daisy, Hart, Thomas C., Hawkins, Sophia, Heath, Paul T., Hill, Helen, Hillson, Kushalinii, Horsington, Bryn, Hou, Mimi M., Howe, Elizabeth, Howell, Nicola, Joe, Carina, Jones, Elizabeth, Kasanyinga, Mwila, Keen, Jade, Kelly, Sarah, Kerr, David, Khan, Liaquat, Khozoee, Baktash, Kinch, Jasmin, Kinch, Patrick, Koleva, Stanislava, Kwok, Jonathan, Larkworthy, Colin W., Lawrie, Alison M., Lazarus, Rajeka, Lees, Emily A., Li, Grace, Libri, Vincenzo, Lillie, Patrick J., Linder, Aline, Long, Fei, Lopez Ramon, Raquel, Mabbett, Reece, Makinson, Rebecca, Marinou, Spyridoula, Marlow, Emma, Marshall, Julia L., Mazur, Olga, McEwan, Joanne, McGregor, Alastair C., Mokaya, Jolynne, Morey, Ella, Morshead, Gertraud, Morter, Richard, Muller, Jilly, Mweu, Philomena, Noristani, Rabiullah, Owino, Nelly, Polo Peralta Alvarez, Marco, Platt, Abigail, Pollock, Katrina M., Poulton, Ian, Provstgaard-Morys, Samuel, Pulido-Gomez, David, Rajan, Matthew, Ramos Lopez, Fernando, Ritchie, Adam, Roberts, Hannah, Rollier, Christine, Rudiansyah, Indra, Sanders, Katherine, Saunders, Jack E., Seddiqi, Samiullah, Sharpe, Hannah R., Shaw, Robert, Silva-Reyes, Laura, Singh, Nisha, Smith, David J., Smith, Catherine C., Smith, Andrew, Spencer, Alexandra J., Stuart, Arabella S.V., Sutherland, Rebecca, Szigeti, Anna, Tang, Karly, Thomas, Merin, Thomas, Tonia M., Thompson, Amber, Thomson, Emma C., Török, Estée M., Toshner, Mark, Tran, Nguyen, Trivett, Rose, Turnbull, Iain, Turner, Cheryl, Turner, David P.J., Ulaszewska, Marta, Vichos, Iason, Walker, Laura, Watson, Marion E., Whelan, Conor, White, Rachel, Williams, Sarah J., Williams, Christopher J.A., Wright, Daniel, Yao, Andy, Flaxman, Amy, Marchevsky, Natalie G, Jenkin, Daniel, Aboagye, Jeremy, Aley, Parvinder K, Angus, Brian, Belij-Rammerstorfer, Sandra, Bibi, Sagida, Bittaye, Mustapha, Cappuccini, Federica, Cicconi, Paola, Clutterbuck, Elizabeth A, Davies, Sophie, Dejnirattisai, Wanwisa, Dold, Christina, Ewer, Katie J, Folegatti, Pedro M, Fowler, Jamie, Hill, Adrian V S, Kerridge, Simon, Minassian, Angela M, Mongkolsapaya, Juthathip, Mujadidi, Yama F, Plested, Emma, Ramasamy, Maheshi N, Robinson, Hannah, Sanders, Helen, Sheehan, Emma, Smith, Holly, Snape, Matthew D, Song, Rinn, Woods, Danielle, Screaton, Gavin, Gilbert, Sarah C, Voysey, Merryn, Pollard, Andrew J, and Lambe, Teresa
Published: 2021
Full Text: View/download PDF

16. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Author: Munro, Alasdair P S, Bartholomew, Jazz, Presland, Laura, Horswill, Sarah, Warren, Sarah, Varkonyi-Clifford, Sophie, Saich, Stephen, Adams, Kirsty, Ricamara, Marivic, Turner, Nicola, Yee Ting, Nicole Y, Whittley, Sarah, Rampling, Tommy, Desai, Amisha, Brown, Claire H, Qureshi, Ehsaan, Gokani, Karishma, Naker, Kush, Kellett Wright, Johanna K, Williams, Rachel L, Riaz, Tawassal, Penciu, Florentina D, Di Maso, Claudio, Howe, Elizabeth G, Vichos, Iason, Ghulam Farooq, Mujtaba, Noristani, Rabiullah, Yao, Xin L, Oldfield, Neil J, Hammersley, Daniel, Belton, Sue, Royal, Simon, San Francisco Ramos, Alberto, Hultin, Cecilia, Galiza, Eva P, Shiham, Farah, Solórzano, Carla, Sainsbury, Hannah, Davies, Kelly, Ambrose, Pauline, Hitchins, Lisa, Baker, Natalie, Leung, Stephanie, Fothergill, Ross, Godwin, Kerry, Buttigieg, Karen, Shaik, Imam, Brown, Phill, Knight, Chanice, Lall, Paminder, Allen, Lauren, Liu, Xinxue, Shaw, Robert H, Stuart, Arabella S V, Greenland, Melanie, Aley, Parvinder K, Andrews, Nick J, Cameron, J Claire, Charlton, Sue, Clutterbuck, Elizabeth A, Collins, Andrea M, Dinesh, Tanya, England, Anna, Faust, Saul N, Ferreira, Daniela M, Finn, Adam, Green, Christopher A, Hallis, Bassam, Heath, Paul T, Hill, Helen, Lambe, Teresa, Lazarus, Rajeka, Libri, Vincenzo, Long, Fei, Mujadidi, Yama F, Plested, Emma L, Provstgaard-Morys, Samuel, Ramasamy, Maheshi N, Ramsay, Mary, Read, Robert C, Robinson, Hannah, Singh, Nisha, Turner, David P J, Turner, Paul J, Walker, Laura L, White, Rachel, Nguyen-Van-Tam, Jonathan S, and Snape, Matthew D
Published: 2021
Full Text: View/download PDF

17. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial

Author: Madhi, Shabir A, Koen, Anthonet L, Izu, Alane, Fairlie, Lee, Cutland, Clare L, Baillie, Vicky, Padayachee, Sherman D, Dheda, Keertan, Barnabas, Shaun L, Bhorat, Qasim Ebrahim, Briner, Carmen, Aley, Parvinder K, Bhikha, Sutika, Hermanus, Tandile, Horne, Elizea, Jose, Aylin, Kgagudi, Prudence, Lambe, Teresa, Masenya, Masebole, Masilela, Mduduzi, Mkhize, Nonhlanhla, Moultrie, Andrew, Mukendi, Christian K, Moyo-Gwete, Thandeka, Nana, Amit J, Nzimande, Ayanda, Patel, Faeezah, Rhead, Sarah, Taoushanis, Carol, Thombrayil, Asha, van Eck, Samuel, Voysey, Merryn, Villafana, Tonya L, Vekemans, Johan, Gilbert, Sarah C, Pollard, Andrew J, Moore, Penny L, and Kwatra, Gaurav
Published: 2021
Full Text: View/download PDF

18. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

Author: Watson, Marion E.E., Song, Rinn, Cicconi, Paola, Minassian, Angela M., Bibi, Sagida, Kerridge, Simon, Singh, Nisha, Green, Catherine M., Douglas, Alexander D., Lawrie, Alison M., Clutterbuck, Elizabeth A., Frater, John, Ewer, Katie J, Ogbe, Ane, Pace, Mathew, Adele, Sandra, Adland, Emily, Alagaratnam, Jasmini, Aley, Parvinder K, Ali, Mohammad, Ansari, M Azim, Bara, Anna, Bittaye, Mustapha, Broadhead, Samantha, Brown, Anthony, Brown, Helen, Cappuccini, Federica, Cooney, Enya, Dejnirattisai, Wanwisa, Dold, Christina, Fairhead, Cassandra, Fok, Henry, Folegatti, Pedro M, Fowler, Jamie, Gibbs, Charlotte, Goodman, Anna L, Jenkin, Daniel, Jones, Mathew, Makinson, Rebecca, Marchevsky, Natalie G, Mujadidi, Yama F, Nguyen, Hanna, Parolini, Lucia, Petersen, Claire, Plested, Emma, Pollock, Katrina M, Ramasamy, Maheshi N, Rhead, Sarah, Robinson, Hannah, Robinson, Nicola, Rongkard, Patpong, Ryan, Fiona, Serrano, Sonia, Tipoe, Timothy, Voysey, Merryn, Waters, Anele, Zacharopoulou, Panagiota, Barnes, Eleanor, Dunachie, Susanna, Goulder, Philip, Klenerman, Paul, Screaton, Gavin R, Winston, Alan, Hill, Adrian V S, Gilbert, Sarah C, Pollard, Andrew J, Fidler, Sarah, Fox, Julie, and Lambe, Teresa
Published: 2021
Full Text: View/download PDF

19. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Author: Ewer, Katie J., Barrett, Jordan R., Belij-Rammerstorfer, Sandra, Sharpe, Hannah, Makinson, Rebecca, Morter, Richard, Flaxman, Amy, Alderson, Jennifer, Bittaye, Mustapha, Dold, Christina, Provine, Nicholas M., Aboagye, Jeremy, Fowler, Jamie, Silk, Sarah E., Aley, Parvinder K., Bellamy, Duncan, and Wright, Daniel
Subjects: T cells -- Physiological aspects, Biological sciences, Health
Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus Disease 2019 (COVID-19), has caused a global pandemic, and safe, effective vaccines are urgently needed.sup.1. Strong, Th1-skewed T cell responses can drive protective humoral and cell-mediated immune responses.sup.2 and might reduce the potential for disease enhancement.sup.3. Cytotoxic T cells clear virus-infected host cells and contribute to control of infection.sup.4. Studies of patients infected with SARS-CoV-2 have suggested a protective role for both humoral and cell-mediated immune responses in recovery from COVID-19 (refs. .sup.5,6). ChAdOx1 nCoV-19 (AZD1222) is a candidate SARS-CoV-2 vaccine comprising a replication-deficient simian adenovirus expressing full-length SARS-CoV-2 spike protein. We recently reported preliminary safety and immunogenicity data from a phase 1/2 trial of the ChAdOx1 nCoV-19 vaccine (NCT04400838).sup.7 given as either a one- or two-dose regimen. The vaccine was tolerated, with induction of neutralizing antibodies and antigen-specific T cells against the SARS-CoV-2 spike protein. Here we describe, in detail, exploratory analyses of the immune responses in adults, aged 18-55 years, up to 8 weeks after vaccination with a single dose of ChAdOx1 nCoV-19 in this trial, demonstrating an induction of a Th1-biased response characterized by interferon-[gamma] and tumor necrosis factor-[alpha] cytokine secretion by CD4.sup.+ T cells and antibody production predominantly of IgG1 and IgG3 subclasses. CD8.sup.+ T cells, of monofunctional, polyfunctional and cytotoxic phenotypes, were also induced. Taken together, these results suggest a favorable immune profile induced by ChAdOx1 nCoV-19 vaccine, supporting the progression of this vaccine candidate to ongoing phase 2/3 trials to assess vaccine efficacy. A single dose of the ChAdOx1 nCoV-19 vaccine elicits antibodies and cytokine-producing T cells that might help control or prevent SARS-CoV-2 infection., Author(s): Katie J. Ewer [sup.1] , Jordan R. Barrett [sup.1] , Sandra Belij-Rammerstorfer [sup.1] , Hannah Sharpe [sup.1] , Rebecca Makinson [sup.1] , Richard Morter [sup.1] , Amy Flaxman [sup.1] [...]
Published: 2021
Full Text: View/download PDF

20. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Author: Barrett, Jordan R., Belij-Rammerstorfer, Sandra, Dold, Christina, Ewer, Katie J., Folegatti, Pedro M., Gilbride, Ciaran, Halkerston, Rachel, Hill, Jennifer, Jenkin, Daniel, Stockdale, Lisa, Verheul, Marije K., Aley, Parvinder K., Angus, Brian, Bellamy, Duncan, Berrie, Eleanor, Bibi, Sagida, and Bittaye, Mustapha
Subjects: AstraZeneca PLC -- Product development, Immune response -- Health aspects, Viral antibodies -- Health aspects, Antibodies -- Health aspects, Pharmaceutical industry -- Product development, Biological sciences, Health, AZD1222 (Vaccine) -- Physiological aspects -- Testing
Abstract: More than 190 vaccines are currently in development to prevent infection by the novel severe acute respiratory syndrome coronavirus 2. Animal studies suggest that while neutralizing antibodies against the viral spike protein may correlate with protection, additional antibody functions may also be important in preventing infection. Previously, we reported early immunogenicity and safety outcomes of a viral vector coronavirus vaccine, ChAdOx1 nCoV-19 (AZD1222), in a single-blinded phase 1/2 randomized controlled trial of healthy adults aged 18-55 years (NCT04324606). Now we describe safety and exploratory humoral and cellular immunogenicity of the vaccine, from subgroups of volunteers in that trial, who were subsequently allocated to receive a homologous full-dose (SD/SD D56; n = 20) or half-dose (SD/LD D56; n = 32) ChAdOx1 booster vaccine 56 d following prime vaccination. Previously reported immunogenicity data from the open-label 28-d interval prime-boost group (SD/SD D28; n = 10) are also presented to facilitate comparison. Additionally, we describe volunteers boosted with the comparator vaccine (MenACWY; n = 10). In this interim report, we demonstrate that a booster dose of ChAdOx1 nCoV-19 is safe and better tolerated than priming doses. Using a systems serology approach we also demonstrate that anti-spike neutralizing antibody titers, as well as Fc-mediated functional antibody responses, including antibody-dependent neutrophil/monocyte phagocytosis, complement activation and natural killer cell activation, are substantially enhanced by a booster dose of vaccine. A booster dose of vaccine induced stronger antibody responses than a dose-sparing half-dose boost, although the magnitude of T cell responses did not increase with either boost dose. These data support the two-dose vaccine regime that is now being evaluated in phase 3 clinical trials. Two doses of the coronavirus disease 2019 vaccine ChAdOx1 nCoV-19 boost antibody responses and functions in phase 1/2 trial participants., Author(s): Jordan R. Barrett [sup.1] , Sandra Belij-Rammerstorfer [sup.1] , Christina Dold [sup.2] , Katie J. Ewer [sup.1] , Pedro M. Folegatti [sup.1] , Ciaran Gilbride [sup.1] , Rachel Halkerston [...]
Published: 2021
Full Text: View/download PDF

21. Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme

Author: Jolley, Keith A., Ford, Karen, Roberts, Hannah, Palmer, Karen, Suggitt, Debbie, Pemberton, Nicola, Ray, Samantha, Wootton, Mandy, Ladhani, Shamez N., Owens, Daniel, Cathie, Katrina, Royal, Simon, Oldfield, Neil, Ure, Roisin, Richards, Jennifer, Ramsay, Rebecca, Hill, Samantha Thomson, Duale, Kaltun, Carr, Jeremy P., MacLennan, Jenny M., Plested, Emma, Bratcher, Holly B., Harrison, Odile B., Aley, Parvinder K., Bray, James E., Camara, Susana, Rodrigues, Charlene M.C., Davis, Kimberly, Bartolf, Angela, Baxter, David, Cameron, J. Claire, Cunningham, Richard, Faust, Saul N., Fidler, Katy, Gowda, Rohit, Heath, Paul T., Hughes, Stephen, Khajuria, Sujata, Orr, David, Raman, Mala, Smith, Andrew, Turner, David P.J., Whittaker, Elizabeth, Williams, Christopher J., Zipitis, Christos S., Pollard, Andrew J., Oliver, Jennifer, Morales-Aza, Begonia, Lekshmi, Aiswarya, Clark, Stephen A., Borrow, Ray, Christensen, Hannah, Trotter, Caroline, Finn, Adam, Maiden, Martin C., and Snape, Matthew D.
Published: 2022
Full Text: View/download PDF

22. Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland

Author: Ramasamy, Maheshi N, primary, Kelly, Elizabeth J, additional, Seegobin, Seth, additional, Dargan, Paul I, additional, Payne, Ruth, additional, Libri, Vincenzo, additional, Adam, Matthew, additional, Aley, Parvinder K, additional, Martinez-Alier, Nuria, additional, Church, Alison, additional, Jepson, Brett, additional, Khan, Mark, additional, Matthews, Sam, additional, Townsend, G Todd, additional, Vekemans, Johan, additional, Bibi, Sagida, additional, Swanson, Phillip A, additional, Lambe, Teresa, additional, Pangalos, Menelas N, additional, Villafana, Tonya, additional, Pollard, Andrew J, additional, Green, Justin A, additional, Wildman, Eden, additional, Rampling, Tommy, additional, Morris, Sheila, additional, Shoemaker, Kathryn, additional, Aksyuk, Anastasia, additional, Padilla, Marcelino Giune, additional, Roe, Tiffany, additional, Petropoulos, Christos J, additional, Wrin, Terri, additional, Colton, Hayley, additional, Bisnauthsing, Karen, additional, Smith, Catherine, additional, Leeman, Lucy, additional, Galloway, James, additional, Nagra, Deepak, additional, Lazarus, Rajeka, additional, Penciu, Florentina, additional, Hunter, Ewan, additional, Sahdev, Anju, additional, Turner, David, additional, Royal, Simon, additional, Uriel, Alison, additional, Ustianowski, Andrew, additional, Moran, Ed, additional, Green, Christopher, additional, Desai, Amisha, additional, Lakeman, Nicki, additional, Moore, Patrick, additional, Whittington, Ashley, additional, Kobielusz Gembala, Iwona, additional, and Konieczny, Marek, additional
Published: 2023
Full Text: View/download PDF

23. Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study – A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines

Author: Shaw, Robert H., primary, Greenland, Melanie, additional, Stuart, Arabella S.V., additional, Aley, Parvinder K., additional, Andrews, Nick J., additional, Cameron, J. Claire, additional, Charlton, Sue, additional, Clutterbuck, Elizabeth A., additional, Collins, Andrea M., additional, Darton, Tom, additional, Dinesh, Tanya, additional, Duncan, Christopher J.A., additional, Faust, Saul N., additional, Ferreira, Daniela M., additional, Finn, Adam, additional, Goodman, Anna L., additional, Green, Christopher A., additional, Hallis, Bassam, additional, Heath, Paul T., additional, Hill, Helen, additional, Lambe, Teresa, additional, Libri, Vincenzo, additional, Lillie, Patrick J., additional, Morey, Ella, additional, Mujadidi, Yama F., additional, Payne, Ruth, additional, Plested, Emma L., additional, Provstgaard-Morys, Samuel, additional, Ramasamy, Maheshi N., additional, Ramsay, Mary, additional, Read, Robert C., additional, Robinson, Hannah, additional, Screaton, Gavin R., additional, Singh, Nisha, additional, Turner, David P.J., additional, Turner, Paul J., additional, White, Rachel, additional, Nguyen-Van-Tam, Jonathan S., additional, Liu, Xinxue, additional, and Snape, Matthew D., additional
Published: 2023
Full Text: View/download PDF

24. Corrigendum to “Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial” [J Infect 84(6) (2022) 795–813, 5511]

Author: Liu, Xinxue, primary, Munro, Alasdair PS, additional, Feng, Shuo, additional, Janani, Leila, additional, Aley, Parvinder K, additional, Babbage, Gavin, additional, Baxter, David, additional, Bula, Marcin, additional, Cathie, Katrina, additional, Chatterjee, Krishna, additional, Dejnirattisai, Wanwisa, additional, Dodd, Kate, additional, Enever, Yvanne, additional, Qureshi, Ehsaan, additional, Goodman, Anna L., additional, Green, Christopher A, additional, Harndahl, Linda, additional, Haughney, John, additional, Hicks, Alexander, additional, van der Klaauw, Agatha A., additional, Kwok, Jonathan, additional, Libri, Vincenzo, additional, Llewelyn, Martin J, additional, McGregor, Alastair C, additional, Minassian, Angela M., additional, Moore, Patrick, additional, Mughal, Mehmood, additional, Mujadidi, Yama F, additional, Holliday, Kyra, additional, Osanlou, Orod, additional, Osanlou, Rostam, additional, Owens, Daniel R, additional, Pacurar, Mihaela, additional, Palfreeman, Adrian, additional, Pan, Daniel, additional, Rampling, Tommy, additional, Regan, Karen, additional, Saich, Stephen, additional, Serafimova, Teona, additional, Saralaya, Dinesh, additional, Screaton, Gavin R, additional, Sharma, Sunil, additional, Sheridan, Ray, additional, Sturdy, Ann, additional, Supasa, Piyada, additional, Thomson, Emma C, additional, Todd, Shirley, additional, Twelves, Chris, additional, Read, Robert C., additional, Charlton, Sue, additional, Hallis, Bassam, additional, Ramsay, Mary, additional, Andrews, Nick, additional, Lambe, Teresa, additional, Nguyen-Van-Tam, Jonathan S, additional, Cornelius, Victoria, additional, Snape, Matthew D, additional, and Faust, Saul N, additional
Published: 2023
Full Text: View/download PDF

25. Pneumococcal carriage following PCV13 delivered as one primary and one booster dose (1 + 1) compared to two primary doses and a booster (2 + 1) in UK infants

Author: Goldblatt, David, primary, Andrews, Nick J., additional, Sheppard, Carmen L., additional, Rose, Samuel, additional, Aley, Parvinder K., additional, Roalfe, Lucy, additional, Southern, Jo, additional, Robinson, Hannah, additional, Pearce, Emma, additional, Plested, Emma, additional, Johnson, Marina, additional, Litt, David J., additional, Fry, Norman K., additional, Waight, Pauline, additional, Snape, Matthew D., additional, and Miller, Elizabeth, additional
Published: 2023
Full Text: View/download PDF

26. Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials

Author: Voysey, Merryn, primary, Flaxman, Amy, additional, Aboagye, Jeremy, additional, Aley, Parvinder K, additional, Belij-Rammerstorfer, Sandra, additional, Bibi, Sagida, additional, Bittaye, Mustapha, additional, Cappuccini, Federica, additional, Charlton, Sue, additional, Clutterbuck, Elizabeth A, additional, Davies, Sophie, additional, Dold, Christina, additional, Edwards, Nick J, additional, Ewer, Katie J, additional, Faust, Saul N, additional, Folegatti, Pedro M, additional, Fowler, Jamie, additional, Gilbride, Ciaran, additional, Gilbert, Sarah C, additional, Godfrey, Leila, additional, Hallis, Bassam, additional, Humphries, Holly E, additional, Jenkin, Daniel, additional, Kerridge, Simon, additional, Mujadidi, Yama F, additional, Plested, Emma, additional, Ramasamy, Maheshi N, additional, Robinson, Hannah, additional, Sanders, Helen, additional, Snape, Matthew D, additional, Song, Rinn, additional, Thomas, Kelly M, additional, Ulaszewska, Marta, additional, Woods, Danielle, additional, Wright, Daniel, additional, Pollard, Andrew J, additional, and Lambe, Teresa, additional
Published: 2023
Full Text: View/download PDF

27. Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme

Author: Carr, Jeremy P., primary, MacLennan, Jenny M., additional, Plested, Emma, additional, Bratcher, Holly B., additional, Harrison, Odile B., additional, Aley, Parvinder K., additional, Bray, James E., additional, Camara, Susana, additional, Rodrigues, Charlene M.C., additional, Davis, Kimberly, additional, Bartolf, Angela, additional, Baxter, David, additional, Cameron, J. Claire, additional, Cunningham, Richard, additional, Faust, Saul N., additional, Fidler, Katy, additional, Gowda, Rohit, additional, Heath, Paul T., additional, Hughes, Stephen, additional, Khajuria, Sujata, additional, Orr, David, additional, Raman, Mala, additional, Smith, Andrew, additional, Turner, David P.J., additional, Whittaker, Elizabeth, additional, Williams, Christopher J., additional, Zipitis, Christos S., additional, Pollard, Andrew J., additional, Oliver, Jennifer, additional, Morales-Aza, Begonia, additional, Lekshmi, Aiswarya, additional, Clark, Stephen A., additional, Borrow, Ray, additional, Christensen, Hannah, additional, Trotter, Caroline, additional, Finn, Adam, additional, Maiden, Martin C., additional, Snape, Matthew D., additional, Jolley, Keith A., additional, Ford, Karen, additional, Roberts, Hannah, additional, Palmer, Karen, additional, Suggitt, Debbie, additional, Pemberton, Nicola, additional, Ray, Samantha, additional, Wootton, Mandy, additional, Ladhani, Shamez N., additional, Owens, Daniel, additional, Cathie, Katrina, additional, Royal, Simon, additional, Oldfield, Neil, additional, Ure, Roisin, additional, Richards, Jennifer, additional, Ramsay, Rebecca, additional, Hill, Samantha Thomson, additional, and Duale, Kaltun, additional
Published: 2022
Full Text: View/download PDF

28. Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial

Author: Shaw, Robert H, primary, Liu, Xinxue, additional, Stuart, Arabella S V, additional, Greenland, Melanie, additional, Aley, Parvinder K, additional, Andrews, Nick J, additional, Cameron, J Claire, additional, Charlton, Sue, additional, Clutterbuck, Elizabeth A, additional, Collins, Andrea M, additional, Dejnirattisai, Wanwisa, additional, Dinesh, Tanya, additional, Faust, Saul N, additional, Ferreira, Daniela M, additional, Finn, Adam, additional, Green, Christopher A, additional, Hallis, Bassam, additional, Heath, Paul T, additional, Hill, Helen, additional, Lambe, Teresa, additional, Lazarus, Rajeka, additional, Libri, Vincenzo, additional, Long, Fei, additional, Mujadidi, Yama F, additional, Plested, Emma L, additional, Morey, Ella R, additional, Provstgaard-Morys, Samuel, additional, Ramasamy, Maheshi N, additional, Ramsay, Mary, additional, Read, Robert C, additional, Robinson, Hannah, additional, Screaton, Gavin R, additional, Singh, Nisha, additional, Turner, David P J, additional, Turner, Paul J, additional, Vichos, Iason, additional, Walker, Laura L, additional, White, Rachel, additional, Nguyen-Van-Tam, Jonathan S, additional, Snape, Matthew D, additional, Munro, Alasdair P.S., additional, Bartholomew, Jazz, additional, Presland, Laura, additional, Horswill, Sarah, additional, Warren, Sarah, additional, Varkonyi-Clifford, Sophie, additional, Saich, Stephen, additional, Adams, Kirsty, additional, Ricamara, Marivic, additional, Turner, Nicola, additional, Yee Ting, Nicole Y., additional, Whittley, Sarah, additional, Rampling, Tommy, additional, Desai, Amisha, additional, Brown, Claire H., additional, Qureshi, Ehsaan, additional, Gokani, Karishma, additional, Naker, Kush, additional, Kellett Wright, Johanna K., additional, Williams, Rachel L., additional, Riaz, Tawassal, additional, Penciu, Florentina D., additional, Carson, Amy, additional, Di Maso, Claudio, additional, Mead, Gracie, additional, Howe, Elizabeth G., additional, Ghulam Farooq, Mujtaba, additional, Noristani, Rabiullah, additional, Yao, Xin L., additional, Oldfield, Neil J., additional, Hammersley, Daniel, additional, Belton, Sue, additional, Royal, Simon, additional, San Francisco Ramos, Alberto, additional, Hultin, Cecilia, additional, Galiza, Eva P., additional, Crook, Rebecca, additional, Bula, Marcin, additional, Fyles, Fred, additional, Burhan, Hassan, additional, Maelin, Flora, additional, Hughes, Elen, additional, and Okenyi, Emmanuel, additional
Published: 2022
Full Text: View/download PDF

29. Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus

Author: Fidler, Sarah, primary, Fox, Julie, additional, Tipoe, Timothy, additional, Longet, Stephanie, additional, Tipton, Tom, additional, Abeywickrema, Movin, additional, Adele, Sandra, additional, Alagaratnam, Jasmini, additional, Ali, Mohammad, additional, Aley, Parvinder K, additional, Aslam, Suhail, additional, Balasubramanian, Anbhu, additional, Bara, Anna, additional, Bawa, Tanveer, additional, Brown, Anthony, additional, Brown, Helen, additional, Cappuccini, Federica, additional, Davies, Sophie, additional, Fowler, Jamie, additional, Godfrey, Leila, additional, Goodman, Anna L, additional, Hilario, Kathrine, additional, Hackstein, Carl-Philipp, additional, Mathew, Moncy, additional, Mujadidi, Yama F, additional, Packham, Alice, additional, Petersen, Claire, additional, Plested, Emma, additional, Pollock, Katrina M, additional, Ramasamy, Maheshi N, additional, Robinson, Hannah, additional, Robinson, Nicola, additional, Rongkard, Patpong, additional, Sanders, Helen, additional, Serafimova, Teona, additional, Spence, Niamh, additional, Waters, Anele, additional, Woods, Danielle, additional, Zacharopoulou, Panagiota, additional, Barnes, Eleanor, additional, Dunachie, Susanna, additional, Goulder, Philip, additional, Klenerman, Paul, additional, Winston, Alan, additional, Hill, Adrian V S, additional, Gilbert, Sarah C, additional, Carroll, Miles, additional, Pollard, Andrew J, additional, Lambe, Teresa, additional, Ogbe, Ane, additional, and Frater, John, additional
Published: 2022
Full Text: View/download PDF

30. Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial

Author: Madhi, Shabir A, primary, Kwatra, Gaurav, additional, Richardson, Simone I, additional, Koen, Anthonet L, additional, Baillie, Vicky, additional, Cutland, Clare L, additional, Fairlie, Lee, additional, Padayachee, Sherman D, additional, Dheda, Keertan, additional, Barnabas, Shaun L, additional, Bhorat, Qasim Ebrahim, additional, Briner, Carmen, additional, Ahmed, Khatija, additional, Aley, Parvinder K, additional, Bhikha, Sutika, additional, Bhorat, A E, additional, Esmail, Aliasgar, additional, Horne, Elizea, additional, Kaldine, Haajira, additional, Mukendi, Christian K, additional, Madzorera, Vimbai Sharon, additional, Manamela, Nelia P, additional, Masilela, Mduduzi, additional, Hermanus, S Tandile, additional, Motlou, Thopisang, additional, Mzindle, Nonkululeko, additional, Oelofse, Suzette, additional, Patel, Faeezah, additional, Rhead, Sarah, additional, Rossouw, Lindie, additional, Taoushanis, Carol, additional, van Eck, Samuel, additional, Lambe, Teresa, additional, Gilbert, Sarah C, additional, Pollard, Andrew J, additional, Moore, Penny L, additional, and Izu, Alane, additional
Published: 2022
Full Text: View/download PDF

31. Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine

Author: Voysey, Merryn, Costa Clemens, Sue Ann, Madhi, Shabir A, Weckx, Lily Yin, Folegatti, Pedro M, Aley, Parvinder K, Angus, Brian John, Baillie, Vicky, Barnabas, Shaun L, Bhorat, Qasim E, Bibi, Sagida, Briner, Carmen, Cicconi, Paola, Clutterbuck, Elizabeth, Collins, Andrea M, Cutland, Clare, Darton, Thomas, Dheda, Keertan, Douglas, Alexander D, Duncan, Christopher JA, Emary, Katherine RW, Ewer, Katie, Flaxman, Amy, Fairlie, Lee, Faust, Saul N, Feng, Shuo, Ferreira, Daniela M, Finn, Adam, Galiza, Eva, Goodman, Anna L, Green, Catherine M, Green, Christopher A, Greenland, Melanie, Hill, Catherine, Hill, Helen C, Hirsch, Ian, Izu, Alane, Jenkin, Daniel, Kerridge, Simon, Koen, Anthonet, Kwatra, Gaurav, Lazarus, Rajeka, Libri, Vincenzo, Lillie, Patrick J, Marchevsky, Natalie, Marshall, Richard P, Mendes, Ana Verena Almeida, Milan, Eveline P, Minassian, Angela M, McGregor, Alastair C, Farooq Mujadidi, Yama, Nana, Anusha, Payadachee, Sherman D, Phillips, Daniel J, Pittella, Ana, Plested, Emma, Pollock, Katrina M, Ramasamy, Maheshi N, Robinson, Hannah, Schwarzbold, Alexandre V, Smith, Andrew, Song, Rinn, Snape, Matthew D, Sprinz, Eduardo, Sutherland, Rebecca K, Thomson, Emma C, Török, Mili Estée, Toshner, Mark, Turner, David PJ, Vekemans, Johan, Villafana, Tonya L, White, Thomas, Williams, Christopher J, Hill, Adrian VS, Lambe, Teresa, Gilbert, Sarah C, Pollard, Andrew, and Group, Oxford COVID Vaccine Trial
Published: 2022
Full Text: View/download PDF

32. Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)

Author: Emary, Katherine RW, Golubchik, Tanya, Aley, Parvinder K, Ariani, Cristina V, Angus, Brian John, Bibi, Sagida, Blane, Beth, Bonsall, David, Cicconi, Paola, Charlton, Sue, Clutterbuck, Elizabeth, Collins, Andrea M, Cox, Tony, Darton, Thomas, Dold, Christina, Douglas, Alexander D, Duncan, Christopher JA, Ewer, Katie, Flaxman, Amy, Faust, Saul N, Ferreira, Daniela M, Feng, Shuo, Finn, Adam, Folegatti, Pedro M, Fuskova, Michelle, Galiza, Eva, Goodman, Anna L, Green, Catherine M, Green, Christopher A, Greenland, Melanie, Hallis, Bassam, Heath, Paul T, Hay, Jodie, Hill, Helen C, Jenkin, Daniel, Kerridge, Simon, Lazarus, Rajeka, Libri, Vincenzo, Lillie, Patrick J, Ludden, Catherine, Marchevsky, Natalie, Minassian, Angela M, McGregor, Alastair C, Farooq Mujadidi, Yama, Phillips, Daniel J, Plested, Emma, Pollock, Katrina M, Robinson, Hannah, Smith, Andrew, Song, Rinn, Snape, Matthew D, Sutherland, Rebecca K, Thomson, Emma C, Toshner, Mark, Turner, David PJ, Vekemans, Johan, Villafana, Tonya L, Williams, Christopher J, Hill, Adrian VS, Lambe, Teresa, Gilbert, Sarah C, Voysey, Merryn, Ramasamy, Maheshi N, Pollard, Andrew, Consortium, COVID-19 Genomics UK COG-UK, and Group, Oxford COVID Vaccine Trial
Published: 2022
Full Text: View/download PDF

33. Hypoxic Regulation of Ca2+ Signalling in Astrocytes and Endothelial Cells

Author: PEERS, CHRIS, ALEY, PARVINDER K., BOYLE, JOHN P., PORTER, KAREN E., PEARSON, HUGH A., SMITH, IAN F., KEMP, PAUL J., BACK, NATHAN, editor, COHEN, IRUN R., editor, KRITCHEVSKY, DAVID, editor, LAJTHA, ABEL, editor, PAOLETTI, RODOLFO, editor, Hayashida, Yoshiaki, editor, Gonzalez, Constancio, editor, and Kondo, Hisatake, editor
Published: 2006
Full Text: View/download PDF

34. Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV

Author: Ogbe, Ane, primary, Pace, Matthew, additional, Bittaye, Mustapha, additional, Tipoe, Timothy, additional, Adele, Sandra, additional, Alagaratnam, Jasmini, additional, Aley, Parvinder K., additional, Ansari, M. Azim, additional, Bara, Anna, additional, Broadhead, Samantha, additional, Brown, Anthony, additional, Brown, Helen, additional, Cappuccini, Federica, additional, Cinardo, Paola, additional, Dejnirattisai, Wanwisa, additional, Ewer, Katie J., additional, Fok, Henry, additional, Folegatti, Pedro M., additional, Fowler, Jamie, additional, Godfrey, Leila, additional, Goodman, Anna L., additional, Jackson, Bethany, additional, Jenkin, Daniel, additional, Jones, Mathew, additional, Longet, Stephanie, additional, Makinson, Rebecca A., additional, Marchevsky, Natalie G., additional, Mathew, Moncy, additional, Mazzella, Andrea, additional, Mujadidi, Yama F., additional, Parolini, Lucia, additional, Petersen, Claire, additional, Plested, Emma, additional, Pollock, Katrina M., additional, Rajeswaran, Thurkka, additional, Ramasamy, Maheshi N., additional, Rhead, Sarah, additional, Robinson, Hannah, additional, Robinson, Nicola, additional, Sanders, Helen, additional, Serrano, Sonia, additional, Tipton, Tom, additional, Waters, Anele, additional, Zacharopoulou, Panagiota, additional, Barnes, Eleanor, additional, Dunachie, Susanna, additional, Goulder, Philip, additional, Klenerman, Paul, additional, Screaton, Gavin R., additional, Winston, Alan, additional, Hill, Adrian V.S., additional, Gilbert, Sarah C., additional, Carroll, Miles, additional, Pollard, Andrew J., additional, Fidler, Sarah, additional, Fox, Julie, additional, Lambe, Teresa, additional, and Frater, John, additional
Published: 2022
Full Text: View/download PDF

35. Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.

Author: Fidler, Sarah, Fox, Julie, Tipoe, Timothy, Longet, Stephanie, Tipton, Tom, Abeywickrema, Movin, Adele, Sandra, Alagaratnam, Jasmini, Ali, Mohammad, Aley, Parvinder K, Aslam, Suhail, Balasubramanian, Anbhu, Bara, Anna, Bawa, Tanveer, Brown, Anthony, Brown, Helen, Cappuccini, Federica, Davies, Sophie, Fowler, Jamie, and Godfrey, Leila
Subjects: HIV infections, HIV-positive persons, KRUSKAL-Wallis Test, COVID-19, IMMUNIZATION, SARS-CoV-2, COVID-19 vaccines, QUANTITATIVE research, MANN Whitney U Test, HIGHLY active antiretroviral therapy, QUALITATIVE research, ENZYME-linked immunosorbent assay, DESCRIPTIVE statistics, DATA analysis software
Abstract: Background People with human immunodeficiency virus (HIV) on antiretroviral therapy (ART) with good CD4 T-cell counts make effective immune responses following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are few data on longer term responses and the impact of a booster dose. Methods Adults with HIV were enrolled into a single arm open label study. Two doses of ChAdOx1 nCoV-19 were followed 12 months later by a third heterologous vaccine dose. Participants had undetectable viraemia on ART and CD4 counts >350 cells/µL. Immune responses to the ancestral strain and variants of concern were measured by anti-spike immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA), MesoScale Discovery (MSD) anti-spike platform, ACE-2 inhibition, activation induced marker (AIM) assay, and T-cell proliferation. Findings In total, 54 participants received 2 doses of ChAdOx1 nCoV-19. 43 received a third dose (42 with BNT162b2; 1 with mRNA-1273) 1 year after the first dose. After the third dose, total anti-SARS-CoV-2 spike IgG titers (MSD), ACE-2 inhibition, and IgG ELISA results were significantly higher compared to Day 182 titers (P <.0001 for all 3). SARS-CoV-2 specific CD4+ T-cell responses measured by AIM against SARS-CoV-2 S1 and S2 peptide pools were significantly increased after a third vaccine compared to 6 months after a first dose, with significant increases in proliferative CD4+ and CD8+ T-cell responses to SARS-CoV-2 S1 and S2 after boosting. Responses to Alpha, Beta, Gamma, and Delta variants were boosted, although to a lesser extent for Omicron. Conclusions In PWH receiving a third vaccine dose, there were significant increases in B- and T-cell immunity, including to known variants of concern (VOCs). [ABSTRACT FROM AUTHOR]
Published: 2023
Full Text: View/download PDF

36. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Author: Dejnirattisai, Wanwisa, primary, Huo, Jiandong, additional, Zhou, Daming, additional, Zahradník, Jiří, additional, Supasa, Piyada, additional, Liu, Chang, additional, Duyvesteyn, Helen M.E., additional, Ginn, Helen M., additional, Mentzer, Alexander J., additional, Tuekprakhon, Aekkachai, additional, Nutalai, Rungtiwa, additional, Wang, Beibei, additional, Dijokaite, Aiste, additional, Khan, Suman, additional, Avinoam, Ori, additional, Bahar, Mohammad, additional, Skelly, Donal, additional, Adele, Sandra, additional, Johnson, Sile Ann, additional, Amini, Ali, additional, Ritter, Thomas G., additional, Mason, Chris, additional, Dold, Christina, additional, Pan, Daniel, additional, Assadi, Sara, additional, Bellass, Adam, additional, Omo-Dare, Nicola, additional, Koeckerling, David, additional, Flaxman, Amy, additional, Jenkin, Daniel, additional, Aley, Parvinder K., additional, Voysey, Merryn, additional, Costa Clemens, Sue Ann, additional, Naveca, Felipe Gomes, additional, Nascimento, Valdinete, additional, Nascimento, Fernanda, additional, Fernandes da Costa, Cristiano, additional, Resende, Paola Cristina, additional, Pauvolid-Correa, Alex, additional, Siqueira, Marilda M., additional, Baillie, Vicky, additional, Serafin, Natali, additional, Kwatra, Gaurav, additional, Da Silva, Kelly, additional, Madhi, Shabir A., additional, Nunes, Marta C., additional, Malik, Tariq, additional, Openshaw, Peter J.M., additional, Baillie, J. Kenneth, additional, Semple, Malcolm G., additional, Townsend, Alain R., additional, Huang, Kuan-Ying A., additional, Tan, Tiong Kit, additional, Carroll, Miles W., additional, Klenerman, Paul, additional, Barnes, Eleanor, additional, Dunachie, Susanna J., additional, Constantinides, Bede, additional, Webster, Hermione, additional, Crook, Derrick, additional, Pollard, Andrew J., additional, Lambe, Teresa, additional, Paterson, Neil G., additional, Williams, Mark A., additional, Hall, David R., additional, Fry, Elizabeth E., additional, Mongkolsapaya, Juthathip, additional, Ren, Jingshan, additional, Schreiber, Gideon, additional, Stuart, David I., additional, Screaton, Gavin R., additional, Conlon, Christopher, additional, Deeks, Alexandra S., additional, Frater, John, additional, Frending, Lisa, additional, Gardiner, Siobhan, additional, Jämsén, Anni, additional, Jeffery, Katie, additional, Malone, Tom, additional, Phillips, Eloise, additional, Rothwell, Lucy, additional, Stafford, Lizzie, additional, Baillie, J Kenneth, additional, Openshaw, Peter JM., additional, Carson, Gail, additional, Alex, Beatrice, additional, Andrikopoulos, Petros, additional, Bach, Benjamin, additional, Barclay, Wendy S., additional, Bogaert, Debby, additional, Chand, Meera, additional, Chechi, Kanta, additional, Cooke, Graham S., additional, da Silva Filipe, Ana, additional, de Silva, Thushan, additional, Docherty, Annemarie B., additional, dos Santos Correia, Gonçalo, additional, Dumas, Marc-Emmanuel, additional, Dunning, Jake, additional, Fletcher, Tom, additional, Green, Christoper A., additional, Greenhalf, William, additional, Griffin, Julian L., additional, Gupta, Rishi K., additional, Harrison, Ewen M., additional, Hiscox, Julian A., additional, Wai Ho, Antonia Ying, additional, Horby, Peter W., additional, Ijaz, Samreen, additional, Khoo, Saye, additional, Law, Andrew, additional, Lewis, Matthew R., additional, Liggi, Sonia, additional, Lim, Wei Shen, additional, Maslen, Lynn, additional, Merson, Laura, additional, Meynert, Alison M., additional, Moore, Shona C., additional, Noursadeghi, Mahdad, additional, Olanipekun, Michael, additional, Osagie, Anthonia, additional, Palmarini, Massimo, additional, Palmieri, Carlo, additional, Paxton, William A., additional, Pollakis, Georgios, additional, Price, Nicholas, additional, Rambaut, Andrew, additional, Robertson, David L., additional, Russell, Clark D., additional, Sancho-Shimizu, Vanessa, additional, Sands, Caroline J., additional, Scott, Janet T., additional, Sigfrid, Louise, additional, Solomon, Tom, additional, Sriskandan, Shiranee, additional, Stuart, David, additional, Summers, Charlotte, additional, Swann, Olivia V., additional, Takats, Zoltan, additional, Takis, Panteleimon, additional, Tedder, Richard S., additional, Thompson, AA Roger, additional, Thomson, Emma C., additional, Thwaites, Ryan S., additional, Turtle, Lance CW., additional, Zambon, Maria, additional, Hardwick, Hayley, additional, Donohue, Chloe, additional, Griffiths, Fiona, additional, Oosthuyzen, Wilna, additional, Donegan, Cara, additional, Spencer, Rebecca G., additional, Norman, Lisa, additional, Pius, Riinu, additional, Drake, Thomas M., additional, Fairfield, Cameron J., additional, Knight, Stephen R., additional, Mclean, Kenneth A., additional, Murphy, Derek, additional, Shaw, Catherine A., additional, Dalton, Jo, additional, Girvan, Michelle, additional, Saviciute, Egle, additional, Roberts, Stephanie, additional, Harrison, Janet, additional, Marsh, Laura, additional, Connor, Marie, additional, Halpin, Sophie, additional, Jackson, Clare, additional, Gamble, Carrol, additional, Plotkin, Daniel, additional, Lee, James, additional, Leeming, Gary, additional, Wham, Murray, additional, Clohisey, Sara, additional, Hendry, Ross, additional, Scott-Brown, James, additional, Shaw, Victoria, additional, McDonald, Sarah E., additional, Keating, Seán, additional, Ahmed, Katie A., additional, Armstrong, Jane A., additional, Ashworth, Milton, additional, Asiimwe, Innocent G., additional, Bakshi, Siddharth, additional, Barlow, Samantha L., additional, Booth, Laura, additional, Brennan, Benjamin, additional, Bullock, Katie, additional, Catterall, Benjamin WA., additional, Clark, Jordan J., additional, Clarke, Emily A., additional, Cole, Sarah, additional, Cooper, Louise, additional, Cox, Helen, additional, Davis, Christopher, additional, Dincarslan, Oslem, additional, Dunn, Chris, additional, Dyer, Philip, additional, Elliott, Angela, additional, Evans, Anthony, additional, Finch, Lorna, additional, Fisher, Lewis WS., additional, Foster, Terry, additional, Garcia-Dorival, Isabel, additional, Gunning, Philip, additional, Hartley, Catherine, additional, Jensen, Rebecca L., additional, Jones, Christopher B., additional, Jones, Trevor R., additional, Khandaker, Shadia, additional, King, Katharine, additional, Kiy, Robyn T., additional, Koukorava, Chrysa, additional, Lake, Annette, additional, Lant, Suzannah, additional, Latawiec, Diane, additional, Lavelle-Langham, Lara, additional, Lefteri, Daniella, additional, Lett, Lauren, additional, Livoti, Lucia A., additional, Mancini, Maria, additional, McDonald, Sarah, additional, McEvoy, Laurence, additional, McLauchlan, John, additional, Metelmann, Soeren, additional, Miah, Nahida S., additional, Middleton, Joanna, additional, Mitchell, Joyce, additional, Murphy, Ellen G., additional, Penrice-Randal, Rebekah, additional, Pilgrim, Jack, additional, Prince, Tessa, additional, Reynolds, Will, additional, Ridley, P. Matthew, additional, Sales, Debby, additional, Shaw, Victoria E., additional, Shears, Rebecca K., additional, Small, Benjamin, additional, Subramaniam, Krishanthi S., additional, Szemiel, Agnieska, additional, Taggart, Aislynn, additional, Tanianis-Hughes, Jolanta, additional, Thomas, Jordan, additional, Trochu, Erwan, additional, van Tonder, Libby, additional, Wilcock, Eve, additional, Zhang, J. Eunice, additional, Flaherty, Lisa, additional, Maziere, Nicole, additional, Cass, Emily, additional, Carracedo, Alejandra Doce, additional, Carlucci, Nicola, additional, Holmes, Anthony, additional, Massey, Hannah, additional, Murphy, Lee, additional, McCafferty, Sarah, additional, Clark, Richard, additional, Fawkes, Angie, additional, Morrice, Kirstie, additional, Maclean, Alan, additional, Wrobel, Nicola, additional, Donnelly, Lorna, additional, Coutts, Audrey, additional, Hafezi, Katarzyna, additional, MacGillivray, Louise, additional, Gilchrist, Tammy, additional, Adeniji, Kayode, additional, Agranoff, Daniel, additional, Agwuh, Ken, additional, Ail, Dhiraj, additional, Aldera, Erin L., additional, Alegria, Ana, additional, Allen, Sam, additional, Angus, Brian, additional, Ashish, Abdul, additional, Atkinson, Dougal, additional, Bari, Shahedal, additional, Barlow, Gavin, additional, Barnass, Stella, additional, Barrett, Nicholas, additional, Bassford, Christopher, additional, Basude, Sneha, additional, Baxter, David, additional, Beadsworth, Michael, additional, Bernatoniene, Jolanta, additional, Berridge, John, additional, Berry, Colin, additional, Best, Nicola, additional, Bothma, Pieter, additional, Chadwick, David, additional, Brittain-Long, Robin, additional, Bulteel, Naomi, additional, Burden, Tom, additional, Burtenshaw, Andrew, additional, Caruth, Vikki, additional, Chambler, Duncan, additional, Chee, Nigel, additional, Child, Jenny, additional, Chukkambotla, Srikanth, additional, Clark, Tom, additional, Collini, Paul, additional, Cosgrove, Catherine, additional, Cupitt, Jason, additional, Cutino-Moguel, Maria-Teresa, additional, Dark, Paul, additional, Dawson, Chris, additional, Dervisevic, Samir, additional, Donnison, Phil, additional, Douthwaite, Sam, additional, Drummond, Andrew, additional, DuRand, Ingrid, additional, Dushianthan, Ahilanadan, additional, Dyer, Tristan, additional, Evans, Cariad, additional, Eziefula, Chi, additional, Fegan, Chrisopher, additional, Finn, Adam, additional, Fullerton, Duncan, additional, Garg, Sanjeev, additional, Garg, Atul, additional, Gkrania-Klotsas, Effrossyni, additional, Godden, Jo, additional, Goldsmith, Arthur, additional, Graham, Clive, additional, Hardy, Elaine, additional, Hartshorn, Stuart, additional, Harvey, Daniel, additional, Havalda, Peter, additional, Hawcutt, Daniel B., additional, Hobrok, Maria, additional, Hodgson, Luke, additional, Hormis, Anil, additional, Jacobs, Michael, additional, Jain, Susan, additional, Jennings, Paul, additional, Kaliappan, Agilan, additional, Kasipandian, Vidya, additional, Kegg, Stephen, additional, Kelsey, Michael, additional, Kendall, Jason, additional, Kerrison, Caroline, additional, Kerslake, Ian, additional, Koch, Oliver, additional, Koduri, Gouri, additional, Koshy, George, additional, Laha, Shondipon, additional, Laird, Steven, additional, Larkin, Susan, additional, Leiner, Tamas, additional, Lillie, Patrick, additional, Limb, James, additional, Linnett, Vanessa, additional, Little, Jeff, additional, Lyttle, Mark, additional, MacMahon, Michael, additional, MacNaughton, Emily, additional, Mankregod, Ravish, additional, Masson, Huw, additional, Matovu, Elijah, additional, McCullough, Katherine, additional, McEwen, Ruth, additional, Meda, Manjula, additional, Mills, Gary, additional, Minton, Jane, additional, Mirfenderesky, Mariyam, additional, Mohandas, Kavya, additional, Mok, Quen, additional, Moon, James, additional, Moore, Elinoor, additional, Morgan, Patrick, additional, Morris, Craig, additional, Mortimore, Katherine, additional, Moses, Samuel, additional, Mpenge, Mbiye, additional, Mulla, Rohinton, additional, Murphy, Michael, additional, Nagel, Megan, additional, Nagarajan, Thapas, additional, Nelson, Mark, additional, Norris, Lillian, additional, O’Shea, Matthew K., additional, Otahal, Igor, additional, Ostermann, Marlies, additional, Pais, Mark, additional, Panchatsharam, Selva, additional, Papakonstantinou, Danai, additional, Paraiso, Hassan, additional, Patel, Brij, additional, Pattison, Natalie, additional, Pepperell, Justin, additional, Peters, Mark, additional, Phull, Mandeep, additional, Pintus, Stefania, additional, Pooni, Jagtur Singh, additional, Planche, Tim, additional, Post, Frank, additional, Price, David, additional, Prout, Rachel, additional, Rae, Nikolas, additional, Reschreiter, Henrik, additional, Reynolds, Tim, additional, Richardson, Neil, additional, Roberts, Mark, additional, Roberts, Devender, additional, Rose, Alistair, additional, Rousseau, Guy, additional, Ruge, Bobby, additional, Ryan, Brendan, additional, Saluja, Taranprit, additional, Schmid, Matthias L., additional, Shah, Aarti, additional, Shanmuga, Prad, additional, Sharma, Anil, additional, Shawcross, Anna, additional, Sizer, Jeremy, additional, Shankar-Hari, Manu, additional, Smith, Richard, additional, Snelson, Catherine, additional, Spittle, Nick, additional, Staines, Nikki, additional, Stambach, Tom, additional, Stewart, Richard, additional, Subudhi, Pradeep, additional, Szakmany, Tamas, additional, Tatham, Kate, additional, Thomas, Jo, additional, Thompson, Chris, additional, Thompson, Robert, additional, Tridente, Ascanio, additional, Tupper-Carey, Darell, additional, Twagira, Mary, additional, Vallotton, Nick, additional, Vancheeswaran, Rama, additional, Vincent-Smith, Lisa, additional, Visuvanathan, Shico, additional, Vuylsteke, Alan, additional, Waddy, Sam, additional, Wake, Rachel, additional, Walden, Andrew, additional, Welters, Ingeborg, additional, Whitehouse, Tony, additional, Whittaker, Paul, additional, Whittington, Ashley, additional, Papineni, Padmasayee, additional, Wijesinghe, Meme, additional, Williams, Martin, additional, Wilson, Lawrence, additional, Winchester, Stephen, additional, Wiselka, Martin, additional, Wolverson, Adam, additional, Wootton, Daniel G., additional, Workman, Andrew, additional, Yates, Bryan, additional, and Young, Peter, additional
Published: 2022
Full Text: View/download PDF

37. Immunogenicity and Reactogenicity of BNT162b2 and mRNA1273 COVID-19 Vaccines Given as Fourth Dose Boosters in the COV-BOOST Randomised Trial Following Two Doses of ChAdOx1 nCov-19 or BNT162b2 and a Third Dose of BNT162b2

Author: Munro, Alasdair P.S, primary, Feng, Shuo, additional, Janani, Leila, additional, Cornelius, Victoria, additional, Aley, Parvinder K., additional, Babbage, Gavin, additional, Baxter, David, additional, Bula, Marcin, additional, Cathie, Katrina, additional, Chatterjee, Krishna, additional, Dodd, Kate, additional, Enever, Yvanne, additional, Qureshi, Ehsaan, additional, Goodman, Anna L., additional, Green, Christopher A., additional, Harndahl, Linda, additional, Haughney, John, additional, Hicks, Alexander, additional, van der Klaauw, Agatha A., additional, Kanji, Nasir, additional, Libri, Vincenzo, additional, Llewelyn, Martin J., additional, McGregor, Alastair C., additional, Minassian, Angela M., additional, Moore, Patrick, additional, Mughal, Mehmood, additional, Farooq Mujadidi, Yama, additional, Holliday, Kyra, additional, Osanlou, Orod, additional, Osanlou, Rostam, additional, Owens, Daniel R., additional, Pacurar, Mihaela, additional, Palfreeman, Adrian, additional, Pan, Daniel, additional, Rampling, Tommy, additional, Regan, Karen, additional, Saich, Stephen, additional, Bawa, Tanveer, additional, Saralaya, Dinesh, additional, Sharma, Sunil, additional, Sheridan, Ray, additional, Maalah, Mina, additional, Thomson, Emma C., additional, Todd, Shirley, additional, Twelves, Chris, additional, Read, Robert C., additional, Charlton, Sue, additional, Hallis, Bassam, additional, Ramsay, Mary E., additional, Andrews, Nick, additional, Lambe, Teresa, additional, Nguyen-Van-Tam, Jonathan S., additional, Snape, Matthew D., additional, Liu, Xinxue, additional, Faust, Saul N., additional, and Group, COV-BOOST Study, additional
Published: 2022
Full Text: View/download PDF

38. Durability of ChAdOx1 nCoV-19 (AZD1222) Vaccine and Hybrid Humoral Immunity Against Variants Including Omicron BA.1 and BA.4 Six Months after Vaccination: A Randomised, Phase 1b/2a Trial

Author: Madhi, Shabir A., primary, Kwatra, Gaurav, additional, Welch, Richard, additional, Koen, Anthonet L., additional, Baillie, Vicky L., additional, Cutland, Clare, additional, Fairlie, Lee, additional, Padayachee, Sherman D., additional, Dheda, Keertan, additional, Barnabas, Shaun L., additional, Bhorat, Qasim Ebrahim, additional, Briner, Carmen, additional, Ahmed, Khatija, additional, Aley, Parvinder K., additional, Bhikha, Sutika, additional, Bhorat, As'ad Ebrahim, additional, Esmail, Aliasgar, additional, Horne, Elizea, additional, Kaldine, Haajira, additional, Mukendi, Christian K., additional, Madzorera, Vimbai Sharon, additional, Manamela, Nelia P., additional, Masilela, Mduduzi, additional, Hermanus, Tandile, additional, Motlou, Thopisang, additional, Mzindle, Nonkululeko, additional, Oelofse, Suzette, additional, Patel, Faeezah, additional, Rhead, Sarah, additional, Rossouw, Lindie, additional, Taoushanis, Carol, additional, van Eck, Samuel, additional, Lambe, Teresa, additional, Gilbert, Sarah C., additional, Pollard, Andrew J., additional, Moore, Penny L., additional, and Izu, Alane, additional
Published: 2022
Full Text: View/download PDF

39. 4CMenB Immunisation in UK Schedule: Persistence of Immune Response to 2 Years of Age Against Capsular Group B Meningococcus, and Immunogenicity Against Capsular Group C and W Meningococcus

Author: Rhead, Sarah, primary, Andrews, Nick, additional, Borrow, Ray, additional, Southern, Jo, additional, Goldblatt, David, additional, Plested, Emma, additional, Chan, Hannah, additional, Harbinson, Holly, additional, Holland, A., additional, Miller, Elizabeth, additional, Robinson, Hannah, additional, Aley, Parvinder K., additional, and Snape, Matthew D., additional
Published: 2022
Full Text: View/download PDF

40. Nicotinic acid adenine dinucleotide phosphate regulates skeletal muscle differentiation via action at two-pore channels

Author: Aley, Parvinder K., Mikolajczyk, Anna M., Munz, Barbara, Churchill, Grant C., Galione, Antony, Berger, Felicitas, and MacLennan, David H.
Published: 2010

41. Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Author: Dejnirattisai, Wanwisa, Huo, Jiandong, Zhou, Daming, Zahradník, Jiří, Supasa, Piyada, Liu, Chang, Duyvesteyn, Helen M.E., Ginn, Helen M., Mentzer, Alexander J., Tuekprakhon, Aekkachai, Nutalai, Rungtiwa, Wang, Beibei, Dijokaite, Aiste, Khan, Suman, Avinoam, Ori, Bahar, Mohammad, Skelly, Donal, Adele, Sandra, Johnson, Sile Ann, Amini, Ali, Ritter, Thomas, Mason, Chris, Dold, Christina, Pan, Daniel, Assadi, Sara, Bellass, Adam, Omo-Dare, Nikki, Koeckerling, David, Flaxman, Amy, Jenkin, Daniel, Aley, Parvinder K, Voysey, Merryn, Clemens, Sue Ann Costa, Naveca, Felipe Gomes, Nascimento, Valdinete, Nascimento, Fernanda, Fernandes da Costa, Cristiano, Resende, Paola Cristina, Pauvolid-Correa, Alex, Siqueira, Marilda M., Baillie, Vicky, Serafin, Natali, Ditse, Zanele, Da Silva, Kelly, Madhi, Shabir, Nunes, Marta C, Malik, Tariq, Openshaw, Peter JM, Baillie, J Kenneth, Semple, Malcolm G, Townsend, Alain R, Huang, Kuan-Ying A., Tan, Tiong Kit, Carroll, Miles W., Klenerman, Paul, Barnes, Eleanor, Dunachie, Susanna J., Constantinides, Bede, Webster, Hermione, Crook, Derrick, Pollard, Andrew J, Lambe, Teresa, Paterson, Neil G., Williams, Mark A., Hall, David R., Fry, Elizabeth E., Mongkolsapaya, Juthathip, Ren, Jingshan, Schreiber, Gideon, Stuart, David I., and Screaton, Gavin R
Subjects: Article
Abstract: SummaryOn the 24th November 2021 the sequence of a new SARS CoV-2 viral isolate spreading rapidly in Southern Africa was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titres of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic as well as Alpha, Beta, Gamma, Delta are substantially reduced or fail to neutralize. Titres against Omicron are boosted by third vaccine doses and are high in cases both vaccinated and infected by Delta. Mutations in Omicron knock out or substantially reduce neutralization by most of a large panel of potent monoclonal antibodies and antibodies under commercial development. Omicron S has structural changes from earlier viruses, combining mutations conferring tight binding to ACE2 to unleash evolution driven by immune escape, leading to a large number of mutations in the ACE2 binding site which rebalance receptor affinity to that of early pandemic viruses.
Published: 2021

42. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Author: Munro, Alasdair P S, primary, Janani, Leila, additional, Cornelius, Victoria, additional, Aley, Parvinder K, additional, Babbage, Gavin, additional, Baxter, David, additional, Bula, Marcin, additional, Cathie, Katrina, additional, Chatterjee, Krishna, additional, Dodd, Kate, additional, Enever, Yvanne, additional, Gokani, Karishma, additional, Goodman, Anna L, additional, Green, Christopher A, additional, Harndahl, Linda, additional, Haughney, John, additional, Hicks, Alexander, additional, van der Klaauw, Agatha A, additional, Kwok, Jonathan, additional, Lambe, Teresa, additional, Libri, Vincenzo, additional, Llewelyn, Martin J, additional, McGregor, Alastair C, additional, Minassian, Angela M, additional, Moore, Patrick, additional, Mughal, Mehmood, additional, Mujadidi, Yama F, additional, Murira, Jennifer, additional, Osanlou, Orod, additional, Osanlou, Rostam, additional, Owens, Daniel R, additional, Pacurar, Mihaela, additional, Palfreeman, Adrian, additional, Pan, Daniel, additional, Rampling, Tommy, additional, Regan, Karen, additional, Saich, Stephen, additional, Salkeld, Jo, additional, Saralaya, Dinesh, additional, Sharma, Sunil, additional, Sheridan, Ray, additional, Sturdy, Ann, additional, Thomson, Emma C, additional, Todd, Shirley, additional, Twelves, Chris, additional, Read, Robert C, additional, Charlton, Sue, additional, Hallis, Bassam, additional, Ramsay, Mary, additional, Andrews, Nick, additional, Nguyen-Van-Tam, Jonathan S, additional, Snape, Matthew D, additional, Liu, Xinxue, additional, Faust, Saul N, additional, Riordan, Andrew, additional, Ustianowski, Andrew, additional, Rogers, Chris A, additional, Hughes, Stephen, additional, Longshaw, Laura, additional, Stockport, Jane, additional, Hughes, Rachel, additional, Grundy, Lynne, additional, Tudor Jones, Lona, additional, Guha, Arpan, additional, Snashall, Emma, additional, Eadsforth, Tom, additional, Reeder, Sally, additional, Storton, Kim, additional, Munusamy, Malathi, additional, Tandy, Bridget, additional, Egbo, Akamino, additional, Cox, Stephen, additional, Ahmed, Nabeela Nazir, additional, Shenoy, Anil, additional, Bousfield, Rachel, additional, Wixted, Donna, additional, Gutteridge, Helen, additional, Mansfield, Becky, additional, Herbert, Christopher, additional, Holliday, Kyra, additional, Calderwood, James, additional, Barker, Dominique, additional, Brandon, Jacqueline, additional, Tulloch, Hayley, additional, Colquhoun, Suzie, additional, Thorp, Helen, additional, Radford, Helen, additional, Evans, Julie, additional, Baker, Helena, additional, Thorpe, Jeanette, additional, Batham, Sally, additional, Hailstone, Jessica, additional, Phillips, Rachael, additional, Kumar, Dileep, additional, Westwell, Fran, additional, Makia, Fiona, additional, Hopkins, NinaSimone, additional, Barcella, Lara, additional, Mpelembue, Mushiya, additional, dabagh, Maja, additional, lang, Matilda, additional, khan, Farida, additional, Adebambo, Olumide, additional, Chita, Sunder, additional, Corrah, Tumena, additional, Whittington, Ashley, additional, John, Laurence, additional, Roche, Siobhan, additional, Wagstaff, Lynda, additional, Farrier, Adam, additional, Bisnauthsing, Karen, additional, Serafimova, Teona, additional, Nanino, Elisa, additional, Cooney, Enya, additional, Wilson-Goldsmith, Jaimie, additional, Nguyen, Hanna, additional, Mazzella, Andrea, additional, Jackson, Beth, additional, Aslam, Suahil, additional, Bawa, Tanveer, additional, Broadhead, Samantha, additional, Farooqi, Sadaf, additional, Piper, Jo, additional, Weighell, Rowena, additional, Pickup, Lorinda, additional, Shamtally, Djamila, additional, Domingo, Jason, additional, Kourampa, Evgenia, additional, Hale, Colin, additional, Gibney, Jennifer, additional, Stackpoole, Michael, additional, Rashid-Gardner, Zalina, additional, Lyon, Rebecca, additional, McDonnell, Chloe, additional, Cole, Christine, additional, Stewart, Anna, additional, McMillan, Gillian, additional, Savage, Mary, additional, Beckett, Helen, additional, Moorbey, Chantelle, additional, Desai, Amisha, additional, Brown, Claire, additional, Naker, Kush, additional, Qureshi, Ehsaan, additional, Trinham, Charlotte, additional, Sabine, Charlotte, additional, Moore, Sophie, additional, Hurdover, Steve, additional, Justice, Edwin, additional, Smith, David, additional, Plested, Emma, additional, Ferreira Da Silva, Carla, additional, White, Rachel, additional, Robinson, Hannah, additional, Cifuentes, Liliana, additional, Morshead, Gertraud, additional, Drake-Brockman, Rachael, additional, Kinch, Patrick, additional, Kasanyinga, Mwila, additional, Clutterbuck, Elizabeth A., additional, Bibi, Sagida, additional, Stuart, Arabella SV, additional, Shaw, Robert H, additional, Singh, Michael, additional, Champaneri, Trishna, additional, Irwin, Margaret, additional, Khan, Mohammed, additional, Kownacka, Alicja, additional, Nabunjo, Martha, additional, Osuji, Carool, additional, Hladkiwskyj, John, additional, Galvin, Dominic, additional, Patel, Gita, additional, Mouland, Johanna, additional, Longhurst, Beverley, additional, Moon, Maria, additional, Giddins, Beth, additional, Pereira Dias Alves, Carlota, additional, Richmond, Leah, additional, Minnis, Christine, additional, Baryschpolec, Sonia, additional, Elliott, Scott, additional, Fox, Lauren, additional, Graham, Victoria, additional, Baker, Natalie, additional, Godwin, Kerry, additional, Buttigieg, Karren, additional, Knight, Chanice, additional, Brown, Phillip, additional, Lall, Paminder, additional, Shaik, Imam, additional, Chiplin, Emily, additional, Brunt, Emily, additional, Leung, Stephanie, additional, Allen, Lauren, additional, Thomas, Steve, additional, Fraser, Sara, additional, Choi, Bea, additional, Gouriet, Jade, additional, Freedman, Andrew, additional, Perkins, Jonathan, additional, Gowland, Andrew, additional, Macdonald, Jonathan, additional, Seenan, John Paul, additional, Starinskij, Igor, additional, Seaton, Andrew, additional, Peters, Erica, additional, Singh, Stephen, additional, Gardside, Ben, additional, Bonnaud, Avril, additional, Davies, Ceri, additional, Gordon, Elizabeth, additional, Keenan, Samantha, additional, Hall, Jane, additional, Wilkins, Suzanne, additional, Tasker, Suzanne, additional, James, Rob, additional, Seath, Ingrid, additional, Littlewood, Kelly, additional, Newman, Joseph, additional, Boubriak, Iryna, additional, Suggitt, Debbie, additional, Haydock, Helen, additional, Bennett, Sara, additional, Woodyatt, Wiesia, additional, Hughes, Kerry, additional, Bell, Judith, additional, Coughlan, Tricia, additional, van Welsenes, Donald, additional, Kamal, Mohammed, additional, Cooper, Chris, additional, Tunstall, Simon, additional, Ronan, Nicholas, additional, Cutts, Rebecca, additional, Dare, Tracey, additional, Yim, Yee Ting Nicole, additional, Whittley, Sarah, additional, Ricamara, Marivic, additional, Hamal, Shama, additional, Adams, Kirsty, additional, Baker, Holly, additional, Driver, Kimberley, additional, Turner, Nicola, additional, Rawlins, Todd, additional, Roy, Subarna, additional, Merida-Morillas, Marta, additional, Sakagami, Yukari, additional, Andrews, Antonette, additional, Goncalves cordeiro, Lillian, additional, Stokes, Matthew, additional, Ambihapathy, Wythehi, additional, Spencer, Joanne, additional, Parungao, Nina, additional, Berry, Lisa, additional, Cullinane, James, additional, Presland, Laura, additional, Ross-Russell, Amy, additional, Warren, Sarah, additional, Baker, Jonathan, additional, Oliver, Abigail, additional, Buadi, Amanda, additional, Lee, Kim, additional, Haskell, Louise, additional, Romani, Rossana, additional, Bentley, Ian, additional, Whitbred, Tim, additional, Fowler, Simon, additional, Gavin, John, additional, Magee, Alan, additional, Watson, Tara, additional, Nightingale, Kari, additional, Marius, Phedra, additional, Summerton, Eloise, additional, Locke, Emily, additional, Honey, Thomas, additional, Lingwood, Aidan, additional, de la Haye, Anastasia, additional, Elliott, Ryan Stephen, additional, Underwood, Karen, additional, King, Mikayala, additional, Davies-Dear, Sharon, additional, Horsfall, Emily, additional, Chalwin, Olivia, additional, Burton, Holly, additional, Edwards, Christopher J, additional, Welham, Benjamin, additional, Garrahy, Sarah, additional, Hall, Fran, additional, Ladikou, Eleni, additional, Mullan, Dee, additional, Hansen, Daniel, additional, Campbell, Marion, additional, Dos Santos, Filipa, additional, Habash-Bailey, Haniah, additional, Lakeman, Nicki, additional, Branney, Debbie, additional, Vamplew, Luke, additional, Hogan, Alison, additional, Frankham, Jorden, additional, Wiselka, Martin, additional, Vail, Dennyl, additional, Wenn, Victoria, additional, Renals, Valerie, additional, Ellis, Kate, additional, Lewis-Taylor, Jessica, additional, Magan, Javier, additional, Hardy, Anna, additional, and Appleby, Kim, additional
Published: 2021
Full Text: View/download PDF

43. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial

Author: Lazarus, Rajeka, primary, Baos, Sarah, additional, Cappel-Porter, Heike, additional, Carson-Stevens, Andrew, additional, Clout, Madeleine, additional, Culliford, Lucy, additional, Emmett, Stevan R, additional, Garstang, Jonathan, additional, Gbadamoshi, Lukuman, additional, Hallis, Bassam, additional, Harris, Rosie A, additional, Hutton, David, additional, Jacobsen, Nick, additional, Joyce, Katherine, additional, Kaminski, Rachel, additional, Libri, Vincenzo, additional, Middleditch, Alex, additional, McCullagh, Liz, additional, Moran, Ed, additional, Phillipson, Adrian, additional, Price, Elizabeth, additional, Ryan, John, additional, Thirard, Russell, additional, Todd, Rachel, additional, Snape, Matthew D, additional, Tucker, David, additional, Williams, Rachel Lauren, additional, Nguyen-Van-Tam, Jonathan S, additional, Finn, Adam, additional, Rogers, Chris A, additional, Adams, Kirsty, additional, Alaee, Seema, additional, Aley, Parvinder K., additional, Allum, Emma, additional, Anthony, Sally, additional, Ashton, Kate, additional, Awal, Tanya, additional, Barnett, Liz, additional, Barratt, Alison, additional, Barron, Charlotte, additional, Baum, Holly, additional, Beard, Chloe, additional, Bennett, Lorna, additional, Bird, Samuel, additional, Bishop, Sarah, additional, Bisset, Jess, additional, Bodalia, Pritesh, additional, Bowles, Jane, additional, Bowyer, Catherine, additional, Bradburn, Kirstie, additional, Bray, Jonathan J.H., additional, Bressington, Catherine, additional, Brimfield, Matthew, additional, Broad, Lauren, additional, Brown, Pauline, additional, Brydon-Hill, Ruth, additional, Burge, Sharon, additional, Carmichael, David, additional, Chohan, Gurjit, additional, Clark, Tonia, additional, Close, Adrianne, additional, Coleman, Tom, additional, Cowley, Claire, additional, Cranfield, Charlotte, additional, Cross, Eleanor, additional, D'Agostino, Alyssa, additional, D'Arcangelo, Silvia, additional, David Otter, Ashley, additional, Davies, Kate, additional, Davies, Catrin, additional, Davies, Ru, additional, Davies, Louisa, additional, Driver, Kimberley, additional, Eglinton, Charlotte, additional, Ekblad, Charlotte, additional, Eldridge, Emma, additional, Evans, Teriann, additional, Evans, Mim, additional, Evans, Isabel, additional, F Mujadidi, Yama, additional, Farrow, Amanda, additional, Faulkner, Beverley, additional, Feltham, Sally, additional, Figueirido, Susan, additional, Ford, Jamie, additional, Foxwell, David, additional, Frayling, Sharon, additional, Gardiner, Sophie, additional, Gooch, Karen E., additional, Goodwin, Jayne, additional, Halliday, Alice, additional, Hamal, Shama, additional, Harrhy, Sarah, additional, Harris, Andrew, additional, Haxton, Lesley, additional, Haynes, Matthew, additional, Hazell, Mae, additional, Hembrough, Tracey, additional, Hewson, Jacqueline, additional, Hicks, Bethany, additional, Higgins, Thomas, additional, Hill, Michelle, additional, Hills, Alex, additional, Hilton, Zoe, additional, Hitchings, Benjamin, additional, Hua, Cheryl, additional, Iftikhar, Hina, additional, Iqbal, Attya, additional, Jones, Laura, additional, Jones, Nicola, additional, Kellett Wright, Johanna, additional, Kidd, Sarah, additional, Kirby, Alison, additional, Knibbs, Lucy, additional, Lamb, Jenny, additional, Langton, Helen, additional, Leach, Rwth, additional, Lewis-Clarke, Phoebe, additional, Lloyd, Amy, additional, Maclean, Kirsty, additional, Manning, Nicola, additional, Marriott, Anthony, additional, McFadzean, Isobel Joy, additional, McLaughlin, Maeve, additional, McQueen, Alison, additional, Mills, Bianca, additional, Naik, Gurudutt, additional, Nicholls, Lisa, additional, Norman, Chris, additional, Northcott, Keren, additional, Nyland, Kerry, additional, Oliver, Catherine, additional, Oliver, Elizabeth, additional, Oliver, Jennifer, additional, Owen, Diana, additional, Paterson, Jemma, additional, Pearce, Lauren, additional, Pegler, Suzannah, additional, Price, Zoe, additional, Pynsent, William B., additional, Ramos, Lidia, additional, Rampling, Tommy, additional, Rea, David, additional, Regan, Karen, additional, Riaz, Tawassal, additional, Ricamara, Marivic, additional, Rice, Danielle, additional, Rich, Melody, additional, Roots, Marianne, additional, Ryan, Kathryn Ann, additional, Sakagami, Yukari, additional, Salem, Ahmed, additional, Salter-Hewitt, Jade, additional, Samuels, Michelle, additional, Santoloce, Silvia, additional, Seaman, Siwan, additional, Seneviratne, Michael, additional, Shankland, Sara, additional, Silva, Louise, additional, Smart, Katie, additional, Smith, Rachel M., additional, Smith, Joyce, additional, Stringer, Rebecca, additional, Talbot, Helen, additional, Tarling, Teresa, additional, Taylor, Sarah Louise, additional, Thomas, Amy, additional, Tilzey, Grace, additional, Townley, Gina, additional, Trembath, Lisa, additional, Turkentine, Kate, additional, Turner, Kelly, additional, Tyler, Jenny, additional, Ugoji, Jacinta, additional, Wale, Katharine, additional, Walker-Smith, Terrie, additional, Walton, Maggie, additional, Warnes, Barbara, additional, Whittley, Sarah, additional, Williams, Jennie, additional, Williams, Gail, additional, Williamson, Kevin, additional, Yim, Yee Ting Nicole, additional, and Youlden, Nicola, additional
Published: 2021
Full Text: View/download PDF

44. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Author: Liu, Xinxue, Shaw, Robert H, Stuart, Arabella S V, Greenland, Melanie, Aley, Parvinder K, Andrews, Nick J, Cameron, J. Claire, Charlton, Sue, Clutterbuck, Elizabeth A, Collins, Andrea M, Dinesh, Tanya, England, Anna, Faust, Saul N, Ferreira, Daniela M, Finn, Adam, Green, Christopher A, Hallis, Bassam, Heath, Paul T, Hill, Helen, Lambe, Teresa, Lazarus, Rajeka, Libri, Vincenzo, Long, Fei, Mujadidi, Yama F, Plested, Emma L, Provstgaard-Morys, Samuel, Ramasamy, Maheshi N, Ramsay, Mary, Read, Robert C, Robinson, Hannah, Singh, Nisha, Turner, David P.J., Turner, Paul J, Walker, Laura L, White, Rachel, Nguyen-Van-Tam, Jonathan S., Snape, Matthew D, Munro, Alasdair P S, Bartholomew, Jazz, Presland, Laura, Horswill, Sarah, Warren, Sarah, Varkonyi-Clifford, Sophie, Saich, Stephen, Adams, Kirsty, Ricamara, Marivic, Turner, Nicola, Yee Ting, Nicole Y, Whittley, Sarah, Rampling, Tommy, Desai, Amisha, Brown, Claire H, Qureshi, Ehsaan, Gokani, Karishma, Naker, Kush, Kellett Wright, Johanna K, Williams, Rachel L, Riaz, Tawassal, Penciu, Florentina D, Di Maso, Claudio, Howe, Elizabeth G, Vichos, Iason, Ghulam Farooq, Mujtaba, Noristani, Rabiullah, Yao, Xin L, Oldfield, Neil J, Hammersley, Daniel, Belton, Sue, Royal, Simon, San Francisco Ramos, Alberto, Hultin, Cecilia, Galiza, Eva P, Shiham, Farah, Sainsbury, Hannah, Davies, Kelly, Ambrose, Pauline, Hitchins, Lisa, Baker, Natalie, Leung, Stephanie, Fothergill, Ross, Godwin, Kerry, Buttigieg, Karen, Shaik, Imam, Brown, Phill, Knight, Chanice, Lall, Paminder, and Allen, Lauren
Subjects: parasitic diseases
Abstract: Background: Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate mass COVID-19 immunisation. However, we have previously reported that heterologous schedules incorporating an adenoviral vectored vaccine (ChAdOx1 nCoV-19, AstraZeneca; hereafter referred to as ChAd) and an mRNA vaccine (BNT162b2, Pfizer–BioNTech; hereafter referred to as BNT) at a 4-week interval are more reactogenic than homologous schedules. Here, we report the safety and immunogenicity of heterologous schedules with the ChAd and BNT vaccines. Methods: Com-COV is a participant-blinded, randomised, non-inferiority trial evaluating vaccine safety, reactogenicity, and immunogenicity. Adults aged 50 years and older with no or well controlled comorbidities and no previous SARS-CoV-2 infection by laboratory confirmation were eligible and were recruited at eight sites across the UK. The majority of eligible participants were enrolled into the general cohort (28-day or 84-day prime-boost intervals), who were randomly assigned (1:1:1:1:1:1:1:1) to receive ChAd/ChAd, ChAd/BNT, BNT/BNT, or BNT/ChAd, administered at either 28-day or 84-day prime-boost intervals. A small subset of eligible participants (n=100) were enrolled into an immunology cohort, who had additional blood tests to evaluate immune responses; these participants were randomly assigned (1:1:1:1) to the four schedules (28-day interval only). Participants were masked to the vaccine received but not to the prime-boost interval. The primary endpoint was the geometric mean ratio (GMR) of serum SARS-CoV-2 anti-spike IgG concentration (measured by ELISA) at 28 days after boost, when comparing ChAd/BNT with ChAd/ChAd, and BNT/ChAd with BNT/BNT. The heterologous schedules were considered non-inferior to the approved homologous schedules if the lower limit of the one-sided 97·5% CI of the GMR of these comparisons was greater than 0·63. The primary analysis was done in the per-protocol population, who were seronegative at baseline. Safety analyses were done among participants receiving at least one dose of a study vaccine. The trial is registered with ISRCTN, 69254139. Findings: Between Feb 11 and Feb 26, 2021, 830 participants were enrolled and randomised, including 463 participants with a 28-day prime-boost interval, for whom results are reported here. The mean age of participants was 57·8 years (SD 4·7), with 212 (46%) female participants and 117 (25%) from ethnic minorities. At day 28 post boost, the geometric mean concentration of SARS-CoV-2 anti-spike IgG in ChAd/BNT recipients (12 906 ELU/mL) was non-inferior to that in ChAd/ChAd recipients (1392 ELU/mL), with a GMR of 9·2 (one-sided 97·5% CI 7·5 to ∞). In participants primed with BNT, we did not show non-inferiority of the heterologous schedule (BNT/ChAd, 7133 ELU/mL) against the homologous schedule (BNT/BNT, 14 080 ELU/mL), with a GMR of 0·51 (one-sided 97·5% CI 0·43 to ∞). Four serious adverse events occurred across all groups, none of which were considered to be related to immunisation. Interpretation: Despite the BNT/ChAd regimen not meeting non-inferiority criteria, the SARS-CoV-2 anti-spike IgG concentrations of both heterologous schedules were higher than that of a licensed vaccine schedule (ChAd/ChAd) with proven efficacy against COVID-19 disease and hospitalisation. Along with the higher immunogenicity of ChAd/BNT compared with ChAD/ChAd, these data support flexibility in the use of heterologous prime-boost vaccination using ChAd and BNT COVID-19 vaccines. Funding: UK Vaccine Task Force and National Institute for Health Research.
Published: 2021

45. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Author: Flaxman, Amy, Marchevsky, Natalie G, Jenkin, Daniel, Aboagye, Jeremy, Aley, Parvinder K, Angus, Brian, Belij-Rammerstorfer, Sandra, Bibi, Sagida, Bittaye, Mustapha, Cappuccini, Federica, Cicconi, Paola, Clutterbuck, Elizabeth A, Davies, Sophie, Dejnirattisai, Wanwisa, Dold, Christina, Ewer, Katie J, Folegatti, Pedro M, Fowler, Jamie, Hill, Adrian VS, Kerridge, Simon, Minassian, Angela M, Mongkolsapaya, Juthathip, Mujadidi, Yama F, Plested, Emma, Ramasamy, Maheshi N, Robinson, Hannah, Sanders, Helen, Sheehan, Emma, Smith, Holly, Snape, Matthew D, Song, Rinn, Woods, Danielle, Screaton, Gavin, Gilbert, Sarah C, Voysey, Merryn, Pollard, Andrew J, Lambe, Teresa, and Oxford COVID Vaccine Trial group
Abstract: BACKGROUND: COVID-19 vaccine supply shortages are causing concerns about compromised immunity in some countries as the interval between the first and second dose becomes longer. Conversely, countries with no supply constraints are considering administering a third dose. We assessed the persistence of immunogenicity after a single dose of ChAdOx1 nCoV-19 (AZD1222), immunity after an extended interval (44-45 weeks) between the first and second dose, and response to a third dose as a booster given 28-38 weeks after the second dose. METHODS: In this substudy, volunteers aged 18-55 years who were enrolled in the phase 1/2 (COV001) controlled trial in the UK and had received either a single dose or two doses of 5 × 1010 viral particles were invited back for vaccination. Here we report the reactogenicity and immunogenicity of a delayed second dose (44-45 weeks after first dose) or a third dose of the vaccine (28-38 weeks after second dose). Data from volunteers aged 18-55 years who were enrolled in either the phase 1/2 (COV001) or phase 2/3 (COV002), single-blinded, randomised controlled trials of ChAdOx1 nCoV-19 and who had previously received a single dose or two doses of 5 × 1010 viral particles are used for comparison purposes. COV001 is registered with ClinicalTrials.gov, NCT04324606, and ISRCTN, 15281137, and COV002 is registered with ClinicalTrials.gov, NCT04400838, and ISRCTN, 15281137, and both are continuing but not recruiting. FINDINGS: Between March 11 and 21, 2021, 90 participants were enrolled in the third-dose boost substudy, of whom 80 (89%) were assessable for reactogenicity, 75 (83%) were assessable for evaluation of antibodies, and 15 (17%) were assessable for T-cells responses. The two-dose cohort comprised 321 participants who had reactogenicity data (with prime-boost interval of 8-12 weeks: 267 [83%] of 321; 15-25 weeks: 24 [7%]; or 44-45 weeks: 30 [9%]) and 261 who had immunogenicity data (interval of 8-12 weeks: 115 [44%] of 261; 15-25 weeks: 116 [44%]; and 44-45 weeks: 30 [11%]). 480 participants from the single-dose cohort were assessable for immunogenicity up to 44-45 weeks after vaccination. Antibody titres after a single dose measured approximately 320 days after vaccination remained higher than the titres measured at baseline (geometric mean titre of 66·00 ELISA units [EUs; 95% CI 47·83-91·08] vs 1·75 EUs [1·60-1·93]). 32 participants received a late second dose of vaccine 44-45 weeks after the first dose, of whom 30 were included in immunogenicity and reactogenicity analyses. Antibody titres were higher 28 days after vaccination in those with a longer interval between first and second dose than for those with a short interval (median total IgG titre: 923 EUs [IQR 525-1764] with an 8-12 week interval; 1860 EUs [917-4934] with a 15-25 week interval; and 3738 EUs [1824-6625] with a 44-45 week interval). Among participants who received a third dose of vaccine, antibody titres (measured in 73 [81%] participants for whom samples were available) were significantly higher 28 days after a third dose (median total IgG titre: 3746 EUs [IQR 2047-6420]) than 28 days after a second dose (median 1792 EUs [IQR 899-4634]; Wilcoxon signed rank test p=0·0043). T-cell responses were also boosted after a third dose (median response increased from 200 spot forming units [SFUs] per million peripheral blood mononuclear cells [PBMCs; IQR 127-389] immediately before the third dose to 399 SFUs per milion PBMCs [314-662] by day 28 after the third dose; Wilcoxon signed rank test p=0·012). Reactogenicity after a late second dose or a third dose was lower than reactogenicity after a first dose. INTERPRETATION: An extended interval before the second dose of ChAdOx1 nCoV-19 leads to increased antibody titres. A third dose of ChAdOx1 nCoV-19 induces antibodies to a level that correlates with high efficacy after second dose and boosts T-cell responses. FUNDING: UK Research and Innovation, Engineering and Physical Sciences Research Council, National Institute for Health Research, Coalition for Epidemic Preparedness Innovations, National Institute for Health Research Oxford Biomedical Research Centre, Chinese Academy of Medical Sciences Innovation Fund for Medical Science, Thames Valley and South Midlands NIHR Clinical Research Network, AstraZeneca, and Wellcome.
Published: 2021

46. T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire

Author: Swanson, Phillip A., Padilla, Marcelino, Hoyland, Wesley, McGlinchey, Kelly, Fields, Paul A., Bibi, Sagida, Faust, Saul N., McDermott, Adrian B., Lambe, Teresa, Pollard, Andrew J., Durham, Nicholas M., Kelly, Elizabeth J., Adlou, Syed, Aley, Parvinder K., Angus, Brian, Anslow, Rachel, Baker, Philip, Bansal, Himanshu, Beveridge, Amy, Bridges-Webb, Alice, Ching, Steven, Cicconi, Paola, Clutterbuck, Elizabeth A., Collins, Andrea M., Darton, Thomas C., Demissie, Tesfaye, Dinesh, Tanya, Douglas, Alexander D., Duncan, Christopher J. A., Ewer, Katie J., Felle, Sally, Finn, Adam, Folegatti, Pedro M., Fuskova, Michelle, Gilbert, Sarah C., Goodman, Anna, Green, Christopher A., Harbolick, Elizabeth, Hart, Thomas C., Hayes, Susana, Hill, Adrian V. S., Jenkin, Daniel, Jepson, Brett M., Kasanyinga, Mwila, Kerridge, Simon, Libri, Vincenzo, Lillie, Patrick J., McGregor, Alastair C., Minassian, Angela M., Mujadidi, Yama F., Pilataxi, Fernanda, Plested, Emma, Provstgaard-Morys, Samuel, Ramasamy, Maheshi, Robinson, Hannah, Sanders, Katherine, Smith, Andrew, Snape, Matthew D., Song, Rinn, Sutherland, Rebecca K., Thomson, Emma C., Toshner, Mark, Turner, David P. J., Voysey, Merryn, and Williams, Christopher J.
Subjects: COVID-19 Vaccines, SARS-CoV-2, Immunogenicity, T cell, Vaccination, T-cell receptor, Receptors, Antigen, T-Cell, COVID-19, Biology, Peripheral blood mononuclear cell, Article, T cell mediated immunity, medicine.anatomical_structure, ChAdOx1 nCoV-19, Spike Glycoprotein, Coronavirus, Immunology, medicine, Humans, Receptor, CD8
Abstract: AZD1222 (ChAdOx1 nCoV-19), a replication-deficient simian adenovirus-vectored vaccine, has demonstrated safety, efficacy, and immunogenicity against coronavirus disease 2019 (COVID-19) in clinical trials and real-world studies. We characterized CD4+ and CD8+ T-cell responses induced by AZD1222 vaccination in peripheral blood mononuclear cells (PBMCs) from 280 unique vaccine recipients aged 18–85 years who enrolled in the phase 2/3 COV002 trial. Total spike-specific CD4+ T cell helper type 1 (Th1) and CD8+ T-cell responses were significantly increased in AZD1222-vaccinated adults of all ages following two doses of AZD1222. CD4+ Th2 responses following AZD1222 vaccination were not detected. Furthermore, AZD1222-specific Th1 and CD8+ T cells both displayed a high degree of polyfunctionality in all adult age groups. T-cell receptor (TCR) β sequences from vaccinated participants mapped against TCR sequences known to react to SARS-CoV-2 revealed substantial breadth and depth across the SARS-CoV-2 spike protein for the AZD1222-induced CD4+ and CD8+ T-cell responses. Overall, AZD1222 vaccination induced a robust, polyfunctional Th1-dominated T-cell response, with broad CD4+ and CD8+ T-cell coverage across the SARS-CoV-2 spike protein.One Sentence SummaryPolyfunctional CD4+ and CD8+ T-cell responses are elicited against the SARS-CoV-2 spike protein following vaccination with AZD1222
Published: 2021

47. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 VOC 202012/01 (B.1.1.7), an exploratory analysis of a randomised controlled trial

Author: Emary, Katherine RW, Golubchik, Tanya, Aley, Parvinder K, Ariani, Cristina V, Angus, Brian, Bibi, Sagida, Blane, Beth, Bonsall, David, Cicconi, Paola, Charlton, Sue, Clutterbuck, Elizabeth A, Collins, Andrea M, Cox, Tony, Darton, Thomas C, Dold, Christina, Douglas, Alexander D, Duncan, Christopher JA, Ewer, Katie J, Flaxman, Amy L, Faust, Saul N, Ferreir, Daniela M, Feng, Shuo, Finn, Adam, Folegatti, Pedro M, Fuskova, Michelle, Galiza, Eva, Goodman, Anna L, Green, Catherine M, Green, Christopher A, Greenland, Melanie, Hallis, Bassam, Heath, Paul T, Hay, Jodie, Hill, Helen C, Jenkin, Daniel, Kerridge, Simon, Lazarus, Rajeka, Libri, Vincenzo, Lillie, Patrick J, Ludden, Catherine, Marchevsky, Natalie G, Minassian, Angela M, McGregor, Alastair C, Mujadidi, Yama F, Phillips, Daniel J, Plested, Emma, Pollock, Katrina M, Robinson, Hannah, Smith, Andrew, Song, Rinn, Snape, Matthew D, Sutherland, Rebecca K, Thomson, Emma C, Toshner, Mark, Turner, David PJ, Vekemans, Johan, Villafana, Tonya L, Williams, Christopher J, Hill, Adrian VS, Lambe, Teresa, Gilbert, Sarah C, Voysey, Merryn, Ramasamy, Maheshi N, Pollard, Andrew J, Consortium, The COVID-19 Genomics UK, Project, The AMPHEUS, Group, The Oxford COVID-19 Vaccine Trial, Toshner, Mark [0000-0002-3969-6143], and Apollo - University of Cambridge Repository
Abstract: A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the United Kingdom from November 2020. Here we report efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19, against this variant., COVID-19 Genomics UK is supported by funding from the Medical Research Council, part of UK Research and Innovation, the NIHR, and Genome Research, operating as the Wellcome Sanger Institute.
Published: 2021
Full Text: View/download PDF

48. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Author: Emary, Katherine RW, Golubchik, Tanya, Aley, Parvinder K, Ariani, Cristina V, Angus, Brian, Bibi, Sagida, Blane, Beth, Bonsall, David, Cicconi, Paola, Charlton, Sue, Clutterbuck, Elizabeth A, Collins, Andrea M, Cox, Tony, Darton, Thomas C, Dold, Christina, Douglas, Alexander D, Duncan, Christopher JA, Ewer, Katie J, Flaxman, Amy L, Faust, Saul N, Ferreira, Daniela M, Feng, Shuo, Finn, Adam, Folegatti, Pedro M, Fuskova, Michelle, Galiza, Eva, Goodman, Anna L, Green, Catherine M, Green, Christopher A, Greenland, Melanie, Hallis, Bassam, Heath, Paul T, Hay, Jodie, Hill, Helen C, Jenkin, Daniel, Kerridge, Simon, Lazarus, Rajeka, Libri, Vincenzo, Lillie, Patrick J, Ludden, Catherine, Marchevsky, Natalie G, Minassian, Angela M, McGregor, Alastair C, Mujadidi, Yama F, Phillips, Daniel J, Plested, Emma, Pollock, Katrina M, Robinson, Hannah, Smith, Andrew, Song, Rinn, Snape, Matthew D, Sutherland, Rebecca K, Thomson, Emma C, Toshner, Mark, Turner, David PJ, Vekemans, Johan, Villafana, Tonya L, Williams, Christopher J, Hill, Adrian VS, Lambe, Teresa, Gilbert, Sarah C, Voysey, Merryn, Ramasamy, Maheshi N, Pollard, Andrew J, COVID-19 Genomics UK Consortium, AMPHEUS Project, Oxford COVID-19 Vaccine Trial Group, Toshner, Mark [0000-0002-3969-6143], and Apollo - University of Cambridge Repository
Subjects: Adult, Male, COVID-19 Vaccines, Adolescent, SARS-CoV-2, COVID-19, Middle Aged, Viral Load, Antibodies, Neutralizing, United Kingdom, Young Adult, COVID-19 Nucleic Acid Testing, ChAdOx1 nCoV-19, Humans, Female, Single-Blind Method, Nucleic Acid Amplification Techniques, Pandemics
Abstract: BACKGROUND: A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against this variant. METHODS: Volunteers (aged ≥18 years) who were enrolled in phase 2/3 vaccine efficacy studies in the UK, and who were randomly assigned (1:1) to receive ChAdOx1 nCoV-19 or a meningococcal conjugate control (MenACWY) vaccine, provided upper airway swabs on a weekly basis and also if they developed symptoms of COVID-19 disease (a cough, a fever of 37·8°C or higher, shortness of breath, anosmia, or ageusia). Swabs were tested by nucleic acid amplification test (NAAT) for SARS-CoV-2 and positive samples were sequenced through the COVID-19 Genomics UK consortium. Neutralising antibody responses were measured using a live-virus microneutralisation assay against the B.1.1.7 lineage and a canonical non-B.1.1.7 lineage (Victoria). The efficacy analysis included symptomatic COVID-19 in seronegative participants with a NAAT positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to vaccine received. Vaccine efficacy was calculated as 1 - relative risk (ChAdOx1 nCoV-19 vs MenACWY groups) derived from a robust Poisson regression model. This study is continuing and is registered with ClinicalTrials.gov, NCT04400838, and ISRCTN, 15281137. FINDINGS: Participants in efficacy cohorts were recruited between May 31 and Nov 13, 2020, and received booster doses between Aug 3 and Dec 30, 2020. Of 8534 participants in the primary efficacy cohort, 6636 (78%) were aged 18-55 years and 5065 (59%) were female. Between Oct 1, 2020, and Jan 14, 2021, 520 participants developed SARS-CoV-2 infection. 1466 NAAT positive nose and throat swabs were collected from these participants during the trial. Of these, 401 swabs from 311 participants were successfully sequenced. Laboratory virus neutralisation activity by vaccine-induced antibodies was lower against the B.1.1.7 variant than against the Victoria lineage (geometric mean ratio 8·9, 95% CI 7·2-11·0). Clinical vaccine efficacy against symptomatic NAAT positive infection was 70·4% (95% CI 43·6-84·5) for B.1.1.7 and 81·5% (67·9-89·4) for non-B.1.1.7 lineages. INTERPRETATION: ChAdOx1 nCoV-19 showed reduced neutralisation activity against the B.1.1.7 variant compared with a non-B.1.1.7 variant in vitro, but the vaccine showed efficacy against the B.1.1.7 variant of SARS-CoV-2. FUNDING: UK Research and Innovation, National Institute for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midlands NIHR Clinical Research Network, and AstraZeneca.
Published: 2021

49. Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses

Author: Ogbe, Ane, primary, Pace, Mathew, additional, Bittaye, Mustapha, additional, Tipoe, Timothy, additional, Adele, Sandra, additional, Alagaratnam, Jasmini, additional, Aley, Parvinder K, additional, Ansari, M. Azim, additional, Bara, Anna, additional, Broadhead, Samantha, additional, Brown, Anthony, additional, Brown, Helen, additional, Cappuccini, Federica, additional, Cinardo, Paola, additional, Dejnirattisai, Wanwisa, additional, Ewer, Katie J., additional, Fok, Henry, additional, Folegatti, Pedro M., additional, Fowler, Jamie, additional, Godfrey, Leila, additional, Goodman, Anna L., additional, Jackson, Bethany, additional, Jenkin, Daniel, additional, Jones, Mathew, additional, Longet, Stephanie, additional, Makinson, Rebecca, additional, Marchevsky, Natalie G., additional, Mathew, Moncy, additional, Mazzella, Andrea, additional, Mujadidi, Yama F., additional, Parolini, Lucia, additional, Petersen, Claire, additional, Plested, Emma, additional, Pollock, Katrina M., additional, Rajeswaran, Thurkka, additional, Ramasamy, Maheshi N., additional, Rhead, Sarah, additional, Robinson, Hannah, additional, Robinson, Nicola, additional, Sanders, Helen, additional, Serrano, Sonia, additional, Stockmann, Helen, additional, Tipton, Tom, additional, Waters, Anele, additional, Zacharopoulou, Panagiota, additional, Barnes, Eleanor, additional, Dunachie, Susanna, additional, Goulder, Philip, additional, Klenerman, Paul, additional, Screaton, Gavin R., additional, Winston, Alan, additional, Hill, Adrian V. S., additional, Gilbert, Sarah C., additional, Carroll, Miles, additional, Pollard, Andrew J, additional, Fidler, Sarah, additional, Fox, Julie, additional, Lambe, Teresa, additional, and Frater, John, additional
Published: 2021
Full Text: View/download PDF

50. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

Author: Frater, John, primary, Ewer, Katie J, additional, Ogbe, Ane, additional, Pace, Mathew, additional, Adele, Sandra, additional, Adland, Emily, additional, Alagaratnam, Jasmini, additional, Aley, Parvinder K, additional, Ali, Mohammad, additional, Ansari, M Azim, additional, Bara, Anna, additional, Bittaye, Mustapha, additional, Broadhead, Samantha, additional, Brown, Anthony, additional, Brown, Helen, additional, Cappuccini, Federica, additional, Cooney, Enya, additional, Dejnirattisai, Wanwisa, additional, Dold, Christina, additional, Fairhead, Cassandra, additional, Fok, Henry, additional, Folegatti, Pedro M, additional, Fowler, Jamie, additional, Gibbs, Charlotte, additional, Goodman, Anna L, additional, Jenkin, Daniel, additional, Jones, Mathew, additional, Makinson, Rebecca, additional, Marchevsky, Natalie G, additional, Mujadidi, Yama F, additional, Nguyen, Hanna, additional, Parolini, Lucia, additional, Petersen, Claire, additional, Plested, Emma, additional, Pollock, Katrina M, additional, Ramasamy, Maheshi N, additional, Rhead, Sarah, additional, Robinson, Hannah, additional, Robinson, Nicola, additional, Rongkard, Patpong, additional, Ryan, Fiona, additional, Serrano, Sonia, additional, Tipoe, Timothy, additional, Voysey, Merryn, additional, Waters, Anele, additional, Zacharopoulou, Panagiota, additional, Barnes, Eleanor, additional, Dunachie, Susanna, additional, Goulder, Philip, additional, Klenerman, Paul, additional, Screaton, Gavin R, additional, Winston, Alan, additional, Hill, Adrian V S, additional, Gilbert, Sarah C, additional, Pollard, Andrew J, additional, Fidler, Sarah, additional, Fox, Julie, additional, Lambe, Teresa, additional, Watson, Marion E.E., additional, Song, Rinn, additional, Cicconi, Paola, additional, Minassian, Angela M., additional, Bibi, Sagida, additional, Kerridge, Simon, additional, Singh, Nisha, additional, Green, Catherine M., additional, Douglas, Alexander D., additional, Lawrie, Alison M., additional, and Clutterbuck, Elizabeth A., additional
Published: 2021
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

207 results on '"Aley, Parvinder K"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources